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Summary
Two live, attenuated varicella zoster virus-containing vaccines are available in the United States for prevention o f varicella:
1) a single-antigen varicella vaccine (VARIVAX,® Merck &  Co., Inc., Whitehouse Station, New Jersey), which was licensed in 
the United States in 1995for use among healthy children aged >12 months, adolescents, and adults; and 2) a combination 
measles, mumps, rubella, and varicella vaccine (ProQuad,® Merck &  Co., Inc., Whitehouse Station, New Jersey), which was 
licensed in the United States in 2005for use among healthy children aged 12 months-12years. Initial Advisory Committee on 
Immunization Practices (ACIP) recommendations for prevention o f varicella issued in 1995 (CDC. Prevention o f varicella: 
recommendations o f the Advisory Committee on Immunization Practices [ACIP]. MMWR 1996;45[No. RR-11]) included 
routine vaccination o f children aged 12-18 months, catch-up vaccination o f susceptible children aged 19 months-12 years, and 
vaccination o f susceptible persons who have close contact with persons at high risk for serious complications (e.g., health-care 
personnel and family contacts o f  immunocompromised persons). One dose o f vaccine was recommended for children aged 
12 months-12 years and 2  doses, 4 -8  weeks apart, for persons aged >13 years. In 1999, ACIP updated the recommendations 
(CDC. Prevention ofvaricella: updated recommendations ofthe Advisory Committee on Immunization Practices [ACIP]. MMWR 
1999;48[No. RR-6]) to include establishing child care and school entry requirements, use ofthe vaccine following exposure and 
for outbreak control, use ofthe vaccine for certain children infected with human immunodeficiency virus, and vaccination of 
adolescents and adults at high risk for exposure or transmission.
In June 2005 and June 2006, ACIP adopted new recommendations regarding the use o f live, attenuated varicella vaccines for 
prevention ofvaricella. This report revises, updates, and replaces the 1996and 1999ACIP statements for prevention ofvaricella. 
The new recommendations include 1) implementation o f a routine 2-dose varicella vaccination program for children, with the 
first dose administered at age 12-15  months and the second dose at age 4 -6 years; 2) a second dose catch-up varicella vaccination 
for children, adolescents, and adults who previously had received 1 dose; 3) routine vaccination o f all healthy persons aged 
>13 years without evidence o f immunity; 4) prenatal assessment and postpartum vaccination; 5) expanding the use o f the 
varicella vaccine for HIV-infected children with age-specific C D 4+T  lymphocyte percentages o f 15% -24%  and adolescents 
and adults with CD4+Tlymphocyte counts >200 cells/^L; and 6) establishing middle school, high school, and college entry 
vaccination requirements. ACIP also approved criteria for evidence o f immunity to varicella.
* D uring  the  preparation o f  this report, D alya G uris was an employee with 
th e  D ivision  o f  V iral Diseases, N ational C en te r for Im m u n iza tio n  and 
R espiratory Diseases, C D C . She presently  is em ployed by M erck, Inc., 
W hitehouse Station, N ew  Jersey.
T he m aterial in this report originated in the N ational C enter for 
Im munization and Respiratory Diseases, Anne Schuchat, M D , Director; 
and the Division o f Viral Diseases, Larry Anderson, M D , Director. 
Corresponding preparer: M ona M arin, M D , N ational C enter for 
Im m unization and Respiratory Diseases, C D C , 1600 Clifton Road 
N E , M S A -47, A tlan ta , GA 30333 . Telephone: 404-639-8791 ; 
Fax: 404-639-8665; E-mail: mmarin@ cdc.gov.
Introduction
Varicella is a highly infectious disease caused by the vari­
cella-zoster virus (VZV). Secondary attack rates for this virus 
might reach 90% for susceptible household contacts. VZV 
causes a systemic infection that results typically in lifetime 
immunity. In otherwise healthy persons, clinical illness after 
reexposure is rare.
In 1995, a vaccine to prevent varicella (VARIVAX,® Merck 
&  Co., Inc., Whitehouse Station, New Jersey) was licensed in 
the United States for use among healthy children aged 
>12 months, adolescents, and adults; recommendations o f the 
Advisory Committee on Immunization Practices (ACIP)
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regarding use o f the varicella vaccine have been published pre­
viously (1,2) This report revises, updates, and replaces earlier 
ACIP statements (Table 1).
Methods
In response to increasing reports o f varicella outbreaks among 
highly vaccinated populations (3-6), ACIP’s measles-mumps- 
rubella and varicella (MMRV) workgroup first met in 
February 2004 to review data related to varicella vaccine use 
in the United States since implementation of the vaccination 
program in 1995 and to consider recommendation options 
for improving control ofvaricella disease. The workgroup held 
monthly conference calls and met in person three times a year. 
The workgroup reviewed data on the impact o f the 1-dose 
varicella vaccination program, including data on vaccination 
coverage, changes in varicella epidemiology, transmission from 
vaccinated persons with varicella, vaccine effectiveness, 
immune response to vaccination, evidence of immunity, and 
potential risk factors for vaccine failure. Published and 
unpublished data related to correlates of protection, safety, 
immunogenicity, and efficacy’!’ o f the new quadrivalent 
M MRV vaccine and the immunogenicity and efficacy o f a 
second dose of varicella vaccine also were reviewed. Cost- 
benefit and cost-effectiveness analyses were considered, includ­
ing revised cost-benefit analysis of both the 1- and 2-dose 
programs for children compared with no vaccination program 
and the incremental benefit of a second dose. Presentations 
were made to the full ACIP meetings in October 2004, 
February 2005, June 2005, and June 2006. Recommenda­
tion options were developed and discussed by the MMRV 
workgroup. When definitive research evidence was lacking, 
the recommendations incorporated expert opinion of the 
workgroup members. The workgroup sought input from part­
ner organizations (i.e., the American Academy o f Pediatrics 
[AAP], the American Academy of Family Physicians [AAFP], 
the American College o f Obstetricians and Gynecologists, the 
Council o f State and Territorial Epidemiologists, and the 
Association o f Immunization Managers) and from state pub­
lic health professionals and immunization program directors. 
Proposed recommendations and a draft statement were pre­
sented to the full ACIP in June 2005 and June 2006. After 
deliberations, final ACIP recommendations were approved in 
2005 and 2006. Modifications to the draft statement were 
made following C D C  and external review process to update 
and clarify wording in the document.
Epidemiology of Varicella 
General
V ZV is transmitted from person to person by direct con­
tact, inhalation of aerosols from vesicular fluid of skin lesions 
of acute varicella or zoster, or infected respiratory tract secre­
tions that also might be aerosolized. The virus enters the host 
through the upper-respiratory tract or the conjunctiva.
The average incubation period for varicella is 14—16 days§ 
after exposure to rash; however, this period can vary (range: 
10—21 days). The period of contagiousness o f infected per­
sons is estimated to begin 1—2 days before the onset o f rash 
and to end when all lesions are crusted, typically 4—7 days 
after onset o f rash (7). Persons who have progressive varicella 
(i.e., development o f new lesions for >7 days) might be conta­
gious longer, presumably because their immune response is 
depressed, which allows viral replication to persist. VZV 
remains dormant in sensory-nerve ganglia and might be 
reactivated at a later time, causing herpes zoster (HZ) 
(i.e., shingles), a painful vesicular rash typically appearing in a 
dermatomal distribution o f one or two sensory-nerve roots.
Since implementation of a universal childhood varicella vac­
cination program in 1995, the epidemiology and clinical char­
acteristics of varicella in the United States have changed, with 
substantial declines in morbidity and mortality attributable 
to varicella. No consistent changes in H Z  epidemiology have 
been documented.
Vaccinated persons might develop modified varicella dis­
ease with atypical presentation. Varicella disease that develops 
>42 days after vaccination (i.e., breakthrough varicella) typi­
cally is mild, with <50 skin lesions, low or no fever, and shorter 
(4—6 days) duration of illness. The rash is more likely to be 
predominantly maculopapular rather than vesicular. Never­
theless, breakthrough varicella is contagious.
Prevaccine Era
Before the introduction of varicella vaccine in 1995, vari­
cella was a universal childhood disease in the United States, 
with peak incidence in the spring and an average annual inci­
dence o f 15—16 cases per 1,000 population. On the basis of 
data from the National Health Interview Survey (NHIS) for
1980—1990, an average o f 4 million cases were estimated to 
have occurred annually (annual incidence rate: 15 cases per
1,000 population) (8). Varicella was not a nationally notifi­
able disease when vaccine was introduced in 1995, and sur­
veillance data were limited. In 1994, only 28 states, the District
 ̂ In  this report, efficacy refers to the extent to w hich a specific intervention 
produces a beneficial result under ideal conditions.
§ T h e  en dash in  num eric ranges is used to represent inclusive years, hours, 
days, ages, dosages, or a sequence o f  num bered items.
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TA B LE 1. S u m m a ry  o f re c o m m en d atio n s  o f th e  A d v is o ry  C o m m ittee  on Im m un iza tio n  P ractices  (ACIP) for p reven tion  o f va rice lla  —
U n ite d  S ta te s , 1 996 , 1 999 , a n d  2007____________________________________________________________________________________________________
Category 1996 recommendations 1999 recommendations 2007 recommendations
Routine
childhood
schedules
Adults and 
adolescents 
aged >13 years
Catch-up
vaccination
HIV*-infected
persons
Antenatal
screening
Outbreak control 
vaccination
Postexposure
vaccination
Vaccination
requirements
1 dose recommended at age 12-18 
months
2 doses, 4-8 weeks apart
Recommended for susceptible persons 
who have close contact with persons at 
high risk for serious complications: 1) 
health-care workers and 2) family 
contacts of immunocompromised 
persons
Should be considered for susceptible 
persons at high risk for exposure:
1) persons who live or work in environ­
ments in which transmission of VZV is 
likely (e.g., teachers of young children, 
child care employees, and residents and 
staff members in institutional settings),
2) persons who live and work in 
environments in which transmission can 
occur (e.g., college students, inmates 
and staff members of correctional 
institutions, and military personnel),
3) nonpregnant women of childbearing 
age, and
4) international travelers.
Is desirable for other susceptible 
adolescents
1 dose recommended for all susceptible 
children aged 19 months-12 years (i.e., 
those with no history of varicella or 
vaccination)
Contraindicated
None
None
None
None
No change
2 doses, 4-8 weeks apart 
No change
Recommended for susceptible persons 
at high risk for exposure or transmission:
1) persons who live or work in environ­
ments in which transmission of VZV is 
likely (e.g., teachers of young children, 
day care employees, and residents and 
staff members in institutional settings),
2) persons who live and work in 
environments in which transmissioncan 
occur (e.g., college students, inmates 
and staff members of correctional 
institutions, and military personnel),
3) nonpregnant women of childbearing age,
4) international travelers, and
5) adolescents and adults living in 
households with children.
No change 
No change
2 doses, 3 months apart
Should be considered for asymptomatic 
or mildly symptomatic HIV-infected 
children in CDC immunologic and clinical 
categories N1 or A1 with age-specific 
CD4+ T-lymphocyte percentages >25%
None
Should be considered 
Recommended within 3-5 days
Recommended for children without 
evidence of immunity attending child 
care centers and entering elementary 
school
Should be considered for middle school 
and junior high school students without 
other evidence of immunity
2 doses recommended
• 1st dose at age 12-15 months
• 2nd dose at age 4-6 years
2 doses, 4-8 weeks apart
Recommended for all 
adolescents and adults 
without evidence of immunity
2nd dose recommended for all 
persons who received 1 dose 
previously
2 doses, 3 months apart
Should be considered for HIV- 
infected children with age- 
specific CD4+ T-lymphocyte 
lymphocyte percentages >15%
May be considered for 
adolescents and adults with 
CD4 counts >200/^L.
Recommended prenatal 
assessment and postpartum 
vaccination
Recommended 2-dose 
vaccination policy
No change
Recommended for children 
attending child care centers, 
students in all grade levels, 
and persons attending college 
or other postsecondary 
educational instutitions
* Human immunodeficiency virus.
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of Columbia, and New York City reported cases to C D C ’s 
National Notifiable Disease Surveillance System (NNDSS); 
reporting was passive, with estimated completeness ranging 
from <0.1% to 20% (9).
In multiple studies, age-specific incidence data were derived 
from N H IS and from state and local surveys (8,10,11). Dur­
ing 1980—1990, an estimated 33% o f cases occurred among 
preschool-aged children (i.e., children aged 12 m onths-
4 years), and 44% occurred among school-aged children (i.e., 
children aged 5-9 years) (annual incidence rates: 82.8 and 
91.1 cases per 1,000 children, respectively). Approximately 
90% -92%  of cases occurred among persons aged <15 years, 
and cases occurred rarely among persons aged >50 years. How­
ever, studies using data from state and local surveys conducted 
during 1990-1992 and during 1994-1995 indicated that the 
highest incidence o f varicella occurred among preschool-aged 
rather than school-aged children, indicating that the disease 
was being acquired at earlier ages (10 ,11 ). N ational 
seroprevalence data for 1988-1994 indicated that 95.5% of 
adults aged 20-29 years, 98.9% of adults aged 30-39 years, 
and >99.6% of adults aged >40 years were immune to VZV 
(12). However, for reasons that are not well understood, the 
epidemiology of varicella differs between countries with tem­
perate and tropical climates (13-18). In the majority o f coun­
tries with temperate climates, >90% of persons are infected 
by adolescence whereas in countries with tropical climates, a 
higher proportion of infections are acquired at older ages, which 
results in higher susceptibility among adults (19).
Estimates of the burden of varicella hospitalization varied 
according to the year(s) studied, the source of data, and the 
definitions used for a varicella-related hospitalization (20-23). 
Estimates were higher if varicella was listed as either a princi­
pal or a secondary cause o f hospitalization, in which case some 
incidental varicella hospitalization might have been included. 
During 1988-1995, an estimated 10,632 hospitalizations were 
attributable annually to varicella in the United States (range: 
8,198-16,586) (20). Another study demonstrated an annual 
average o f 15,073 hospitalizations during 1993-1995, but this 
period might have included an epidemic year (22). Overall 
rates o f hospitalization for varicella during 1988-1995 ranged 
from 2.3 to 6.0 cases per 100,000 population. If any vari­
cella-related hospital discharge diagnostic code was included, 
rates varied between 5.0 and 7.0 cases per 100,000 popula­
tion (20-23).
During 1988-1995, persons without severe immuno­
compromising conditions or treatments comprised the larg­
est proportion (89%) of annual varicella-related hospitaliza­
tions (20). Before vaccination, children aged <4 years 
accounted for 43% -44%  of hospitalizations, and persons aged 
>20 years accounted for 32% -33%  (20,22). The rate of
complications from varicella was substantially higher for 
persons aged >20 years and for infants (i.e., children aged 
<1 year). Adults aged >20 years were 13 times more likely to 
be hospitalized when they had varicella than children aged 
5-9 years, and infants aged <1 year were six times more likely 
to be hospitalized than children aged 5-9 years (20). The most 
common complications of varicella that resulted in hospital­
izations were skin and soft tissue infections (especially inva­
sive group A streptococcal in fection s), pneum onia, 
dehydration, and encephalitis. In 1980, an association was 
identified between Reye syndrome and the use of aspirin dur­
ing varicella or influenza-like illness; since then, Reye syn­
drome, which was once considered a common complication 
resulting from varicella infection, has become rare (24-26).
During 1970-1994, the average annual number o f deaths 
for which varicella was recorded as the underlying cause was 
105; the overall average annual varicella mortality rate was 
0.4 deaths per 1 million population. The age distribution of 
varicella deaths has shifted during this period. During 1970­
1974, persons aged <20 years accounted for 80% of varicella 
deaths, compared with 46% during 1990-1994. During 
1970-1994, the average case-fatality rate (CFR) for varicella 
for all ages combined ranged from 2.0 to 3.6 per 100,000 
cases, with higher rates among infants and adults aged >20 
years (27). Although CFRs declined substantially during this 
period, the risk for varicella-related death during 1990-1994 
was still 25 times higher for adults than for children aged 
12 months-4 years (CFR: 21.3 and 0.8 per 100,000 cases, 
respectively). During the same period, 89% of varicella deaths 
among children and 75% of varicella deaths among adults 
occurred in persons without severe underlying immuno­
compromising medical conditions. The most common com­
plications am ong persons who died o f  varicella were 
pneumonia, central nervous system complications (including 
encephalitis), secondary infection, and hemorrhagic condi­
tions. A recent reanalysis of varicella deaths also considered 
varicella when listed as a contributing cause of death in addi­
tion to the underlying cause studied in the previous report (28). 
During 1990-1994, a varicella diagnosis was listed on an aver­
age o f 145 death certificates per year (105 as an underlying 
cause and 40 as a contributing cause), with an overall annual 
varicella mortality rate of 0.6 deaths per 1 million population.
Varicella during pregnancy can have adverse consequences 
for the fetus and infant, including congenital varicella syn­
drome (see Prenatal and Perinatal Exposure). Reliable data on 
the number of cases of congenital varicella syndrome are not 
available. However, on the basis of age-specific varicella inci­
dence (from N H IS), the annual number of births, and the 
risk for congenital varicella syndrome (1.1% overall risk in 
the first 20 weeks of pregnancy), 44 cases of congenital
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varicella syndrome are estimated to have occurred each year 
in the United States during the prevaccine era (29).
Postvaccine Era
In 1995, a varicella vaccine (VARIVAX,® Merck &  Co., Inc., 
Whitehouse Station, New Jersey) was licensed in the United 
States for use among healthy children aged >12 months, ado­
lescents, and adults. At that time, ACIP recommended routine 
varicella vaccination of children aged 12-18 months, catch-up 
vaccination of susceptible children aged 19 months-12 years, 
and vaccination of susceptible persons who have close contact 
with persons at high risk for serious complications (e.g., health­
care workers and family contacts of immunocompromised per­
sons) (1; Table 1). In 1999, ACIP updated the recommendations 
to include child care and school entry requirements, use of the 
vaccine after exposure and for outbreak control, use of the vac­
cine for certain children infected with human immunodeficiency 
virus (HIV), and vaccination of adolescents and adults at high 
risk for exposure or transmission (2 ; Table 1).
During 1997-2005, national varicella vaccination coverage 
among children aged 19-35 months increased from 27% to 
88%, with no statistically significant difference in coverage 
by race or ethnicity (30). In 2005, state-specific varicella vac­
cination coverage ranged from 69% to 96% (31). National 
surveillance data continue to be limited, but passive surveil­
lance data in certain states have documented a decline in 
varicella incidence.
In four states (Illinois, Michigan, Texas, and West Virginia) 
with adequate (>5% o f expected cases during 1990—1994) 
reporting to N N D SS, varicella incidence for 2004 declined 
53%—88% compared with the average incidence for 1990­
1994, with vaccination coverage among children aged 19-35 
months ranging from 82% to 88% (32; C D C , unpublished 
data, 2006). During 2003-2005, the number o f cases increased 
in Illinois and Texas; the biggest increase (56%) occurred in 
Texas (Figure 1). The number o f cases remained stable in 
Michigan (Figure 1) and declined minimally in West Virginia.
In 1995, along with implementation o f the national vacci­
nation program, C D C  instituted active surveillance for vari­
cella in three communities (Antelope Valley, California; Travis 
County, Texas; and West Philadelphia, Pennsylvania) in col­
laboration with state and local health departments to estab­
lish baseline data and to monitor trends in varicella disease 
after introduction o f varicella vaccine. By 2000, vaccination 
coverage among children 19-35 months in these three com­
munities had reached 74% -84% , and reported total varicella 
cases had declined 71% -84%  (33). Although incidence 
declined to the greatest extent (83% -90%) among children 
aged 12 months-4 years, incidence declined in all age groups, 
including infants and adults, indicating the herd immunity 
effects o f the vaccination program. Since 2001, only two sites 
were funded to continue surveillance (Antelope Valley and 
West Philadelphia). By 2005, vaccination coverage in these 
two sites had increased to 90%, and the reduction in inci­
dence had reached 90% and 91%, respectively (34). During
F IG U R E  1. N u m b er o f re p o rte d  c a s e s  o f v a ric e lla  d is e a s e  a m o n g  p e rs o n s  o f  a ll a g e  g ro u p s * an d  e s tim a te d  a n n u a l v a c c in a tio n  
c o v e ra g e  a m o n g  c h ild re n  a g e d  1 9 -3 5  m o n th s ,* by y e a r an d  s ta te  —  M ic h ig a n  a n d  T exas , 1 9 9 0 -2 0 0 5
Michigan Texas
"0
(D
Year Year
‘ Source: National Notifiable Disease Surveillance System. 
t  Source: National Immunization Survey.
6 MMWR June 22, 2007
1996-2005, as vaccination coverage continued to increase, 
the proportion of persons with varicella who had been vacci­
nated increased from 2% to 56%. During 1995-2004, peak 
incidence for varicella cases in active surveillance sites shifted 
from age 3-6  years to age 9-11 years.
After introduction o f vaccine in 1995, the number and rate 
of annual varicella-related hospitalizations declined. In one 
study of a nationally representative sample that was conducted 
during 1993-2001, varicella hospitalizations declined 75% 
(22). In another study, the annual varicella-related hospital­
ization rate declined 88% during 1994-2002 (23) (Figure 2). 
Hospitalization rates declined 100% among infants, and sub­
stantial declines also were recorded in all other age groups (up 
to age 50 years); hospitalization rates declined 91% among 
children aged <10 years, 92% among children and adoles­
cents aged 10-19 years, and 78% among adults aged 20-49 
years. The greater decline in hospitalizations among children 
led to an increase in the proportion  o f  varicella- 
related hospitalizations among adults (40% of hospitalizations 
in 2002 occurred among persons aged >20 years) (23). In the 
combined active surveillance area, varicella-related hospitaliza­
tions declined from 2.4-4.2 hospitalizations per 100,000 popu­
lation during 1995-1998 to 1.5 per 100,000 population in
2000 (33) and to 0.8 per 100,000 population in 2005 (34).
During 1995-2001, the number o f deaths for which vari­
cella was listed as the underlying cause decreased from 115 to 
26 (28) (Figure 3). Since then, the number of deaths declined 
further; 16 deaths were reported in 2003. Age-adjusted mor­
tality rates decreased 66%, from an average o f 0.41 deaths per 
1 million population during 1990-1994 to 0.14 during 1999­
2001. The decline was observed in all age groups <50 years,
F IG U R E  2. V a r ic e lla -re la te d * h o s p ita liz a t io n  ra te s *  a m o n g  
p e rs o n s  a g e d  < 5 0  y e a rs , b y  y e a r a n d  ag e  g ro u p  —  U n ited  
S ta te s , 1 9 9 4 -2 0 0 2
Year
Source: Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact 
o f varicella vaccination on health care utilization. JAMA 2005;294: 
797-802.
* Varicella was the primary diagnosis code. 
tP er 100,000 population.
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Year
Source: Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to 
varicella after implementation of varicella vaccination in the United States. 
N Engl J Med 2005;352:450-8.
* Per 1 million population.
with the greatest reduction (92%) occurring among children 
aged 12 months-4 years (0.09 deaths per 1 million popula­
tion), followed by an 88% reduction among children aged 
5-9 years (0.10 deaths per 1 million population). Deaths 
among persons aged >50 years did not decline to the same 
extent; however, the validity of reported varicella deaths in 
this age group is low (35), and the majority o f these deaths are 
not considered to be caused by varicella. During 1999-2001, 
the average rate of mortality attributed to varicella among all 
racial and ethnic populations was <0.15 deaths per 1 million 
persons. Persons without high-risk conditions (e.g., malignan­
cies, HIV/acquired immunodeficiency syndrome [AIDS], and 
other immune deficiencies) accounted for 92% of deaths 
attributable to varicella. The average rates of deaths for which 
varicella was listed as a contributing cause of death also 
declined during 1999-2001, compared with 1990-1994.
Despite high 1-dose vaccination coverage and the success 
of the vaccination program in reducing varicella morbidity 
and mortality, reports to C D C  from active surveillance sites 
and from states with well-implemented vaccination programs 
and surveillance indicate that in certain states and in one 
active surveillance site, the number of reported varicella cases 
has remained constant or declined minimally, and outbreaks 
have continued to occur. During 2001-2005, outbreaks were 
reported in schools with high varicella vaccination coverage 
(range 96% -100% ) (3,4). The outbreaks were similar in cer­
tain respects: 1) all occurred in elementary schools, 2) vaccine 
effectiveness was similar (range: 72% -85% ), 3) the highest 
attack rates occurred among the younger students, 4) each 
outbreak lasted approximately 2 months, and 5) index cases 
occurred among vaccinated students (although their disease 
was mild). Overall attack rates among vaccinated children var­
ied (range: 11%—17%), with attack rates in certain classrooms 
as high as 40%. These data indicate that even in settings in
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which vaccination coverage was nearly universal and vaccine 
performed as expected, the 1-dose vaccination program could 
not prevent varicella outbreaks completely.
Prenatal and Perinatal Exposure
In the prevaccine era, prenatal infection was uncommon 
because the majority o f women o f childbearing age were 
immune to VZV (12,36). Varicella in pregnant women is 
associated with a risk for VZV transmission to the fetus or 
newborn. Intrauterine VZV infection might result in congeni­
tal varicella syndrome, neonatal varicella, or H Z  during 
infancy or early childhood (3 7 -4 6 ). Infants who are 
exposed prenatally to VZV, even if asymptomatic, might have 
measurable varicella-specific IgM antibody during the new­
born period, have persistent varicella-specific IgG immunity 
after age 1 year without a history of postnatal varicella, or 
demonstrate positive lymphocyte transformation in response 
to VZV antigen (37).
Congenital varicella syndrome was first recognized in 1947 
(40). Congenital varicella syndrome can occur among infants 
born to mothers infected during the first half o f pregnancy 
and might be manifested by low birthweight, cutaneous scar­
ring, limb hypoplasia, microcephaly, cortical atrophy, chori­
oretinitis, cataracts, and other anomalies. In one study, 
incidence o f congenital varicella syndrome was calculated us­
ing aggregate data from nine cohort studies carried out dur­
ing 1986-2002 (47). Rates were 0.6% (4 o f 725) for 2-12 
weeks’ gestation, 1.4% (9 o f 642) for 13-28 weeks, and 0 (0 
of 385) after 28 weeks.
In a prospective study o f 1,373 mothers with varicella dur­
ing pregnancy conducted in the United Kingdom and West 
Germany during 1980-1993, the highest risk (2%) for con­
genital varicella syndrome was observed when maternal infec­
tion occurred during 13-20 weeks’ gestation (43). The risk 
was 0.4% after maternal infection during 0-12 weeks’ gesta­
tion. No cases of congenital varicella syndrome occurred 
among the infants o f366 mothers with H Z during pregnancy. 
Nine isolated cases involving birth defects consistent with con­
genital varicella syndrome have been reported after maternal 
varicella beyond 20 weeks’ gestation (with the latest occur­
ring at 28 weeks) (47,48). In a prospective study, H Z 
occurred during infancy or early childhood in four (0.8%) of 
477 infants who were exposed to VZV during 13-24 weeks’ 
gestation and in six (1.7%) of 345 infants who were exposed 
during 25-36 weeks’ gestation (43).
The onset of varicella in pregnant women from 5 days 
before to 2 days after delivery results in severe varicella infec­
tion in an estimated 17%-30% of their newborn infants. These 
infants are exposed to V Z V  without sufficient maternal
antibody to lessen the severity of disease. The risk for neona­
tal death has been estimated to be 31% among infants whose 
mothers had onset o f rash <4 days before giving birth (45). 
This estimate was made on the basis of a limited number of 
infant deaths and might be higher than the actual risk 
because the study was performed before neonatal intensive 
care was available. In addition, certain cases were not part of 
prospective studies but were reported retrospectively, making 
the results subject to selection bias. When these cases were 
reevaluated subsequently by another investigator, certain 
infants were demonstrated to have been at higher risk for death 
because o f low birthweight; in at least one case, another cause 
o f death was probable (46). Varicella-zoster immune globulin 
(VZIG) has been reported to reduce incidence o f severe neo­
natal varicella disease (49) and therefore is indicated in such 
situations. Nevertheless, the risk for death among neonates 
who do not receive postexposure prophylaxis with VZIG is 
likely to be substantially lower than was estimated previously.
Herpes Zoster Surveillance
After primary infection, VZV persists as a latent infection 
in sensory-nerve ganglia. The virus can reactivate, causing HZ. 
Mechanisms controlling VZV latency are not well understood. 
Risk factors for H Z  include aging, immunosuppression, and 
initial infection with varicella in utero or during early child­
hood (i.e., age <18 months). An estimated 15%—30% of the 
general population experience H Z during their lifetimes 
(50,51); this proportion is likely to increase as life expectancy 
increases. The most common complication of HZ, particu­
larly in older persons, is postherpetic neuralgia (PHN), the 
persistence of sometimes debilitating pain weeks to months 
after resolution of HZ. Life-threatening complications o f HZ 
also can occur; these include herpes ophthalmicus, which can 
lead to blindness. Another severe manifestation is dissemina­
tion, which might involve generalized skin eruptions, and cen­
tral nervous system, pulmonary, hepatic, and pancreatic 
complications. Dissemination, pneumonia, and visceral 
involvement typically are restricted to immunocompromised 
persons. VZV can be transmitted from the lesions o f patients 
who have H Z to susceptible contacts. Although few data are 
available to assess this risk, one household contact study 
reported that the risk for VZV transmission from H Z  was 
approximately 20% ofthe risk for transmission from varicella (52).
Varicella vaccination might alter the risk for H Z  at the level 
of both the individual and the population (i.e., herd immu­
nity). Just as wild-type VZV can cause wild-type HZ, attenu­
ated vaccine virus has the potential to become latent and later 
reactivate to cause vaccine virus strain (also called Oka-strain) 
H Z (53). Multiple studies have evaluated the risk for Oka-strain
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H Z after vaccination of immunocompromised or healthy chil­
dren (54-58). In a study of leukemic children, the rate o f HZ 
after a mean 4.1 years o f follow-up (range: 6 months-10 years) 
was 2% in vaccine recipients and 15% in controls with a his­
tory o f varicella (54). A subset o f 96 o f these vaccine recipients 
was matched prospectively according to chemotherapeutic pro­
tocol with 96 leukemic children who had experienced natural 
varicella. Analysis indicated that the incidence of H Z  was 
approximately three times lower in vaccine recipients (0.80 per 
100 person-years) than in the matched leukemic children who 
had experienced natural varicella (2.46 per 100 person-years) 
(p = 0.01). Data for healthy children are more limited, and 
findings might be influenced by multiple factors (e.g., incom­
plete ascertainment, limited duration of follow up or no follow 
up of subjects of older ages, no comprehensive screening for 
wild-type varicella infection before or after vaccination, or lack 
of testing all cases to distinguish Oka- from wild-type HZ). 
Nonetheless, these studies suggest that the risk for Oka-strain 
H Z after a single dose of varicella vaccine is lower than that 
after wild-type varicella infection (56-58). Over time, the risk 
for and manifestation o f Oka-strain H Z should be examined in 
older persons who are at greater risk for H Z complications. 
Persons who experience varicella infection before vaccination 
(i.e., as a result o f in utero or unapparent infection) or after 
vaccination (i.e., as a result o f breakthrough infection) presum­
ably are latently infected with two strains of VZV. The risk for 
H Z in these persons is unknown. No long-term studies have 
been conducted that compare the risk for Oka-strain H Z  in 
persons who receive 1 dose of varicella vaccine with the risk for 
those who receive 2 doses.
Varicella vaccination also might change the risk for H Z  at 
the population level. With the development o f herd immu­
nity and reduction in the likelihood of exposure, the varicella 
vaccination program prevents wild-type VZV infection among 
vaccine recipients and nonvaccine recipients, eliminating the 
risk for wild-type H Z  in these persons. Reduction in the like­
lihood o f wild-type varicella infection also increases the 
median age for acquiring varicella (although age-specific inci­
dence rates themselves are lower). This reduces the risk for 
varicella infection during early childhood (i.e., age <18 
months), thereby reducing a risk factor for childhood HZ.
Exposure of persons with latent wild-type VZV infection 
to persons with varicella is thought to boost specific immu­
nity, which might contribute to controlling reactivation of 
V ZV and the development o f H Z  (50). Concern has been 
expressed that by providing fewer opportunities for varicella 
exposure among persons with previous wild-type varicella 
infection, reduction in the likelihood o f exposure might 
increase the risk for HZ, possibly within as few as 5 years after
introduction of varicella vaccination (59 ) and reaching a 
vaccination coverage of >90%.
Herpes zoster is not a nationally notifiable disease in the 
United States, and H Z  surveillance has been conducted using 
multiple methods, study sites, or data sources. For certain stud­
ies, baseline data were available before the start o f the varicella 
vaccination program. One study that included baseline data 
was a retrospective analysis o f electronic medical records from 
a health maintenance organization (HMO) during 1992-2002 
(60). This H M O  study indicated that age-adjusted incidence 
o f H Z remained stable during 1992-2002 as incidence of 
varicella decreased (60). Age-adjusted and -specific annual 
incidence rates of H Z  fluctuated slightly over time; the age- 
adjusted rate was highest in 1992, at 4.1 cases per 1,000 per­
son-years, and was 3.7 cases per 1,000 person-years in 2002. 
For other studies initiated in the postvaccine era, baseline data 
are not available (61-63). An analysis o f national incidence 
data from the M edstat database (available at h ttp :// 
www.medstat.com/Products/view/?id=71) demonstrated an 
overall incidence o f H Z in 2000 and 2001 o f 3.2 (95% con­
fidence interval [CI] = 3.1—3.2) per 1,000 person-years (61), 
representing no increase in age-adjusted H Z  in the past 20 
years in the United States compared with earlier published 
data (64). Data from two HM Os in Oregon and Washington 
for 1997-2003 indicated no statistically significant increase 
in H Z incidence rates except among children aged 10-17 years 
(relative risk [RR] = 1.12, CI = 1.05-1.18); these increases 
were attributed to increased use o f oral steroids (62). Another 
study of data gathered from a statewide telephone survey dur­
ing 1999-2003 in Massachusetts demonstrated an increase in 
H Z (63). Age groups particularly affected included persons 
aged 25-44 years and those aged >65 years. Finally, in the 
two active varicella surveillance sites (Antelope Valley, Cali­
fornia, and West Philadelphia, Pennsylvania), active surveil­
lance for H Z  in children aged <20 years has been ongoing 
since 2000. During 2000-2004, incidence of H Z  in children 
aged <10 years declined significantly (p<0.05) from 0.75 to 
0.23 cases per 1,000 children (65; C D C  unpublished data, 
2006). In summary, multiple studies and surveillance data 
demonstrate no consistent trends in H Z incidence in the 
United States since implementation of the varicella vaccina­
tion program in 1995.
Use of Acyclovir to Treat 
and Prevent Varicella
Acyclovir is a synthetic nucleoside analog that inhibits rep­
lication of human herpes viruses, including VZV. Since the 
early 1980s, intravenous acyclovir has been available to treat
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immunocompromised persons who have varicella. When 
administered within 24 hours o f onset o f rash, acyclovir has 
been demonstrated to be effective in reducing varicella- 
associated morbidity and mortality in this population (66—68).
In 1992, the Food and Drug Adm inistration (FDA) 
approved the use o f oral acyclovir for the treatment o f vari­
cella in otherwise healthy children. This approval was made 
on the basis o f placebo-controlled, double-blind studies 
(69,70) that demonstrated the beneficial clinical effects 
(i.e., a decrease in the number o f days in which new lesions 
appeared, the duration of fever, and the severity o f cutaneous 
and systemic signs and symptoms) that occurred when 
acyclovir was administered within 24 hours o f rash onset. No 
serious adverse events occurred during the period of drug 
administration. Administration o f acyclovir did not decrease 
transmission o f varicella or reduce the duration o f absence 
from school. Because few complications occurred (1% -2%), 
these studies could not determine whether acyclovir had a sta­
tistically significant effect on disease severity among healthy 
children. In these studies, antibody titers after infection in 
children receiving acyclovir did not differ substantially from 
titers o f children in the control group (69,70). Clinical trials 
among adolescents and adults have indicated that acyclovir is 
well-tolerated and effective in reducing the duration and 
severity o f clinical illness if the drug is administered within 24 
hours o f rash onset (71—73).
In 1993, AAP’s Committee on Infectious Diseases published 
a statement regarding the use o f acyclovir (74). AAP did not 
consider administration o f acyclovir to healthy children to have 
clinical benefit sufficient to justify its routine administration; 
however, AAP stated that certain circumstances might justify 
its use. AAP recommended that oral acyclovir should be con­
sidered for otherwise healthy persons at increased risk for mod­
erate to severe varicella (e.g., persons aged >12 years, persons 
with chronic cutaneous or pulmonary disorders, persons 
receiving long-term salicylate therapy, and persons receiving 
short, intermittent, or aerosolized courses o f corticosteroids). 
Certain experts also recommend use o f oral acyclovir for 
secondary case-patients who live in the same households as 
infected children (74).
Acyclovir is classified as a Category B drug in the FDA use- 
in-pregnancy rating. Although studies involving animals have 
not indicated teratogenic effects, adequate, well-controlled 
studies in pregnant women have not been conducted. However, 
a prospective registry o f acyclovir use during pregnancy that 
collected data on outcomes o f596 infants whose mothers were 
exposed to systemic acyclovir during the first trimester o f preg­
nancy indicated that the rate and types o f birth defects 
approximated those in the general population (75). AAP has 
not recommended routine use o f oral acyclovir for pregnant
women because the risks and benefits to the fetus and mother 
were unknown. However, in instances o f serious, viral­
mediated complications (e.g., pneumonia), AAP has recom­
mended that intravenous acyclovir should be considered (74).
Two nucleoside analogs, acyclovir and famciclovir, have been 
approved by FDA for treating HZ. If administered within 72 
hours of rash onset, acyclovir has accelerated the rate of cuta­
neous healing and reduced the severity of acute pain in adults 
who have H Z  (76). Oral famciclovir, when administered 
during the same period, has similar efficacy (77).
Acyclovir is not indicated for prophylactic use among 
otherwise healthy children, adolescents, or adults without evi­
dence o f immunity after exposure to varicella. Vaccination is 
the method of choice in these situations. No studies have been 
conducted regarding prophylactic use o f acyclovir among 
immunocompromised persons; therefore, VZIG is recom­
mended in these situations.
Vaccines for Prevention of Varicella
Two live attenuated varicella virus vaccines are licensed in 
the United States for prevention of varicella: single-antigen 
varicella vaccine (VARIVAX,® Merck &  Co., Inc., Whitehouse 
Station, New Jersey) and combination M M RV vaccine 
(ProQuad,® Merck &  Co., Inc., Whitehouse, New Jersey). 
Both vaccines are derived from the Oka strain of live, attenu­
ated VZV. The Oka strain was isolated in Japan (78) in the 
early 1970s from vesicular fluid in a healthy child who had 
natural varicella and was attenuated through sequential propa­
gation  in cultures o f  hum an em bryonic lung cells, 
embryonic guinea-pig cells, and human diploid cells (WI-38). 
The virus in the Oka/Merck vaccine has undergone further 
passage through human diploid-cell cultures (MRC-5) for a 
total of 31 passages.
In 1995, the single-antigen varicella vaccine was licensed in 
the United States for use among healthy persons aged >12 
months. This vaccine is lyophilized; when reconstituted as 
directed in the package insert and stored at room temperature 
for a maximum of 30 minutes, it contains a minimum of 1,350 
plaque forming units (PFUs) o f Oka/Merck VZV in each 0.5 
mL dose (79). Each dose also contains 12.5 mg of hydrolyzed 
gelatin, trace amounts of neomycin and fetal bovine serum, 
25 mg o f sucrose, and trace residual components o f MRC-5 
cells (including D N A  and protein). The vaccine does not 
contain preservatives. Since 1995, >55 million doses have been 
distributed in the United States. Reporting of serious adverse 
events has been rare (see Vaccine-Associated Adverse Events).
In 2005, the combination MMRV vaccine was licensed in 
the United States for use among healthy children aged 
12 months-12 years. The attenuated measles, mumps, and
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rubella vaccine viruses in ProQuad® are identical and o f equal 
titer to those in the measles, mumps, and rubella (MMR) 
vaccine, MMRII® ( 80). The titer o f Oka/Merck VZV is higher 
in MMRV than in single-antigen varicella vaccine, a mini­
mum o f 3.99 log 1 0  PFUs compared with 1,350 PFUs 
(approximately 3.13 log^) in each 0.5 mL dose. The other 
constituents are similar to those in the single-antigen varicella 
vaccine.
Immune Response to Vaccination
In clinical trials o f the single-antigen varicella vaccine con­
ducted before licensure, seroconversion was assessed using lots 
o f vaccine with different amounts o f PFUs and laboratory 
assays with different levels o f sensitivity and specificity. Using 
a specially  developed, sensitive gp-enzym e-linked 
immunosorbent assay (ELISA) test that is not available com­
mercially, seroconversion (defined by the acquisition of any 
detectable varicella antibodies >0.3 gpELISA units) was 
observed at approximately 4-6  weeks after vaccination with 
1 dose o f varicella vaccine in approximately 97% of 6,889 
susceptible children aged 1-12 years (79). The seroconversion 
rate was 98% for children aged 12-15 months and 95% among 
those aged 5-12 years (81). Adolescents aged 13-17 years had 
a lower seroconversion rate (79%) after a single dose o f vac­
cine. A study performed postlicensure used fluorescent 
antibody to membrane antigen (FAMA) titers 16 weeks after 
vaccination to assess serologic response and demonstrated that 
61 (76%) o f 80 healthy child vaccine recipients seroconverted 
(FAMA titers >1:4) after 1 dose o f single-antigen varicella 
vaccine (82).
Primary antibody response to the vaccine at 6 weeks post­
vaccination is correlated with protection against disease 
(83,84). In clinical trials, rates o f breakthrough disease were 
lower among children with varicella antibody titers o f 
>5 gpELISA units than among those with titers o f <5 units 
(84); children with a 6-week postvaccination antibody titer of 
<5 gpELISA units were 3.5 times more likely to have break­
through varicella than those with a titer o f >5 gpELISA units. 
Later studies o f immunogenicity (85) have reported the pro­
portion o f vaccinated children who achieved this antibody 
level instead of seroconversion. After 1 dose o f the single­
antigen varicella vaccine, 86% o f children had gpELISA lev­
els o f >5 units/mL (85). Studies performed using FAMA 
indicated that a titer >1:4 at 16 weeks postvaccination is cor­
related with protection against disease (82). O f healthy per­
sons with a titer o f >1:4 at 16 weeks post vaccination, <1% 
have had varicella after a household exposure (n = 130). In 
contrast, the attack rate among those with a titer o f <1:4 was 
55% (n = 60).
Persistence o f antibody in children after 1 dose o f single­
antigen varicella vaccine was demonstrated in both short- and 
long-term follow-up studies. In a clinical study, the rate of 
antibody persistence detected by gpELISA was nearly 100% 
after 9 years o f follow-up for 277 children (85). Another study 
demonstrated that although antibody titers (detected by 
FAMA) might decline 12—24 months after vaccination, the 
median titer did not change after 1—4 years and even rose 
after 10 years (86). In Japan, V ZV antibodies were present in 
37 (97%) of 38 children who received varicella vaccine 7—10 
years earlier (with titers comparable to those o f 29 children 
who had had natural varicella infection within the previous 
10 years) (87) and in 100% of 25 children when followed for 
as long as 20 years (i.e., antibody levels were higher than those 
observed 10 years earlier) (88). Interpretation o f long-term 
studies is complicated by at least two factors. First, asymp­
tomatic boosting o f vaccine-induced immunity by exposure 
to wild-type VZV is likely. Because varicella vaccine is not 
routinely recommended in Japan, coverage o f children was 
estimated to be low (approximately 20%) during 1991—1993. 
Second, sample sizes were limited as a result o f the decrease in 
the number o f children followed-up with increasing time since 
vaccination.
The second dose o f varicella vaccine in children produced 
an improved immunologic response that is correlated with 
improved protection. A comparative study of healthy chil­
dren who received 1 or 2 doses o f single-antigen varicella vac­
cine administered 3 months apart indicated that a second dose 
provided higher antibody levels as measured by the propor­
tion o f subjects with titers o f >5 gpELISA units and by 
geometric mean titers (GM Ts) and higher efficacy (85; 
Tables 2—4). The proportion of subjects with antibody titers 
o f >5 gpELISA units in the 2-dose recipients was higher 6 
weeks after the second dose than after the first dose (99.6% 
and 85.7%, respectively) and remained high at the end o f the
9-year follow-up period, although the difference between the 
two regimens narrowed (97% and 95%, respectively). G M T 
6 weeks after the second dose was substantially higher than 
that after a single dose (142 and 12, respectively). The differ­
ence in GMTs between the two regimens did not persist over
9 years o f follow-up among subjects who seroconverted after 
vaccination, although GMTs in both regimens remained high 
by the end of the study period. However, receipt o f a second 
dose decreased the rate o f breakthrough varicella significantly 
(3.3-fold) and increased vaccine efficacy (p<0.001). Another 
study that assessed the immunogenicity o f a second dose 
received 4—6 years after the first dose demonstrated a substan­
tial increase in antibody levels in the first 7—10 days in the 
majority o f those tested, indicating an anamnestic response.
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TA B LE  2. H u m o ra l and  c e llu la r im m un e re s p o n s e  am o n g  c h ild re n  a g ed  12 m o n th s -1 2  years  m e asu red  a t 6 w e e k s  p o s tvacc in a tio n , 
by v a c c in e  ty p e  an d  v a c c in a tio n  s c h e d u le  —  U n ite d  S ta te s , 1 9 8 8 -2 0 0 2 _____________________________________________________________
Immune response
6 wks after dose 1
6 wks after dose 2 and 
3 mos between doses
6 wks after dose 2 
at age 4 -6  yrs
Varicella
vaccine* MMRVt
Varicella
vaccine MMRV
Varicella
vaccine MMRV
VZV§ IgG gpELISAH >5 ylmL 85.7%** 91.2%t t 99.6%** 99.2%t t 99.4%§§ 98.9%§§
G M T^ VZV IgG gpELISA ^lmL 12.5** 13.0t t 142.6** 588t t 212.4§§ 317§§
Mean SI*** 28.6 (+l-6.2)ttt 36.9 (+l-9.1)t t t 58.6 (+l-6.5)§§§
* Single-antigen varicella vaccine.
t  Combination measles, mumps, rubella, and varicella vaccine.
§ Varicella zoster virus.
^ Enzyme-linked immunosorbent assay.
** Source: Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr 
Infect Dis J 2004;23:132-7.
t t  Source: Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr 
Infect Dis J 2005;24:665-9.
§§ Source: Reisinger KS, Hoffman Brown ML, Xu J, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year- 
old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics 2006;117:265-72.
^  Geometric mean titer.
*** Stimulation index. Mean SIs from different laboratories and from different studies should not be directly compared.
t t t  Source: Nader S, Bergen R, Sharp M, Arvin A. Comparison of cell-mediated immunity (CMI) to varicella-zoster virus (VZV) in children and adults 
immunized with live attenuated varicella vaccine. J Infect Dis 1995;171:13-7.
§§§ Source: Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years 
after primary immunization. J Infect Dis 1995;172:217-9.
TA B LE  3. T e n -y e a r e ff ic a c y  o f s in g le -a n tig e n  v a r ic e lla  v a c c in e  in p re v e n tin g  v a ric e lla  a fte r  c o m m u n ity  e x p o s u re  a m o n g  c h ild re n  
a g e d  12 m o n th s -1 2  y e a rs , b y  n u m b e r o f v a c c in e  d o s e s  —  U n ite d  S ta te s , 1 9 9 3 -2 0 0 3 ______________________________________________
Average annual rate* o f varicella
No. study
Observed among 
vaccine recipients
Estimated among 
nonimmune children^
Community exposure 
10-year efficacy
No. doses subjects No. cases % CI§ % % CI
1 1,104 60 0.8 0.6-1.0 14.2 94.4 92.9-95.7
2 1,017 17 0.2 0.1-0.4 14.0 98.3 97.3-99.0
* Per 100 children aged 12 months-12 years.
t Estimated rates among nonimmune children were age-adjusted and based on historic data from unvaccinated susceptible children who had exposure 
in the community.
§95% confidence interval.
Source: Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr 
Infect Dis J 2004;23:132-7.
T A B LE  4. T en -ye a r e ff ic a c y  o f s in g le -a n tig e n  v a ric e lla  v a c c in e  in p re v e n tin g  v a ric e lla  a fte r h o u s e h o ld  e x p o s u re  a m o n g  c h ild ren  
a g e d  1 -1 2  y e a rs , by  n u m b e r o f v a c c in e  d o s e s  —  U n ited  S ta te s , 1 9 9 3 -2 0 0 3 _________________________________________________________
Average annual rate* o f varicella
No. children Observed among Estimated among Household exposure
w ith household vaccine recipients nonimmune children^ 10-year efficacy
No. doses exposure No. cases (%) (%) % CI§
1 94 8 8.5 86.8 90.2 83.7-96.7
2 96 3 3.1 86.8 96.4 92.4-100.0
* Per 100 children aged 12 months-12 years.
t Rate among non-immune children is estimated on the basis of historic secondary-attack rates in unvaccinated, susceptible household contacts.
§95% confidence interval.
Source: Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr 
Infect Dis J 2004;23:132-7.
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On the day o f the second dose, G M T was 25.7, compared 
with 143.6 G M T 7—10 days after the second dose; 60% of 
recipients had at least a fourfold increase in antibody titers, 
and an additional 17% had at least a twofold increase (89). 
Three months after the second dose, G M T remained higher 
than on the day o f second dose (119.0 and 25.7, respectively). 
Among children, VZV antibody levels and GMTs after 2 doses 
administered 4—6 years apart were comparable to those 
obtained when the 2 doses were administered 3 months apart.
The combination M MRV vaccine was licensed on the basis 
o f noninferiority o f immunogenicity o f the antigenic compo­
nents compared with M M R and varicella vaccines adminis­
tered concomitantly at separate inspection sites rather than 
on clinical efficacy (80). Clinical studies o f healthy children 
aged 12—23 months indicated that those who received 1 dose 
o f M MRV vaccine had levels o f antibody to measles, mumps, 
rubella, and varicella similar to levels o f children who received
1 dose o f M M R and 1 dose o f varicella vaccines concomi­
tantly at separate injection sites. For the varicella component 
in MMRV, 91.2% (CI = 87.0%—94.4%) o f children achieved 
antibody titers o f >5 gpELISA units/mL 6 weeks after vacci­
nation (90). A subgroup of children received a second dose of 
M MRV vaccine approximately 3 months after the first dose. 
The serologic response (>5 gpELISA units/mL) after 2 doses 
was 99.2% (CI = 97.0% —99.9%) (Table 2). Also, G M T for 
varicella after the second dose o f M MRV vaccine increased 
approximately forty-onefold (90). Administration of combi­
nation M MRV vaccine to healthy children aged 4—6 years 
who had been vaccinated previously with M M R and single­
antigen varicella vaccines resulted in similar antibody levels 
and a twenty-fivefold increase in G M T  levels (91).
Among persons aged >13 years, multiple studies have 
described seroconversion rates after receipt o f the single­
antigen varicella vaccine (range: 72% —94% after 1 dose and 
94% -99%  after a second dose administered 4—8 weeks later) 
(79,92,93). In clinical studies, detectable antibody levels have 
persisted for at least 5 years in 97% o f adolescents and adults 
who were administered 2 doses o f vaccine 4—8 weeks apart 
(79). However, other studies demonstrated that 25%—31% 
of adult vaccine recipients who seroconverted lost detectable 
antibodies (by FAMA) at multiple intervals (range: 1—11 years) 
after vaccination (93,94). For persons who had breakthrough 
disease after exposure to varicella, the severity o f illness or the 
attack rates did not increase over time (95).
Innate (i.e., nonspecific) and adaptive (i.e., humoral and 
cellular) immunity are important in the control o f primary 
varicella infection. The capacity to elicit cell-mediated immu­
nity is important for viral clearance, providing long-term
protection against disease and preventing symptomatic VZV 
reactivation. Studies among children and adults have indi­
cated that breakthrough varicella typically is mild, even among 
vaccine recipients without seroconversion or vaccine recipi­
ents who lost detectable antibody, suggesting that VZV- 
specific cell-mediated immunity affords protection to vaccine 
recipients in the absence o f a detectable antibody response 
(94,95). Studies o f the cellular immune response to vaccina­
tion among children demonstrated that immunization with
1 dose o f varicella vaccine induced VZV-specific T-cell prolif­
eration that was maintained in 26 (90%) of 29 children 1 year 
postvaccination and in 52 (87%) o f 60 children 5 years post­
vaccination (96). In this study, the mean stimulation index 
(SI), a marker o f cell-mediated immunity, was 12.1 after 1 year 
and 22.1 after 5 years. Data obtained at 1 year postvaccina­
tion from a subset o f children in a prelicensure study compar­
ing the immune response among children who received 1 and
2 doses administered 3 months apart demonstrated that the 
varicella-specific lymphocyte proliferation responses were sig­
nificantly higher for recipients o f 2 doses than for recipients 
o f 1 dose (mean SI: 34.7 and 23.1, respectively; p = 0.03) 
(97). In the study o f the 2 doses administered 4—6 years apart, 
results also indicated that the lymphocyte proliferation 
response was significantly higher at 6 weeks and 3 months 
after the second dose than at the same time points after the 
first dose (p<0.01) (89; Table 2).
Among adults, vaccine-induced VZV-specific T-cell prolif­
eration was maintained in 16 (94%) of 17 subjects 1 and
5 years postvaccination (96,98). The mean SI was 9.9 after 
1 year and 22.4 after 5 years.
Correlates of Protection
For children, the varicella antibody response measured by 
gpELISA 6 weeks postvaccination correlates with neutraliz­
ing antibody level, VZV-specific T-cell proliferative responses, 
vaccine efficacy, and long-term protection against varicella after 
exposure to VZV  (83,84,99,100). A titer o f >5 gpELISA 
units/mL is associated with protection against disease although 
it should not be considered an absolute guarantee o f protec­
tion. Breakthrough cases have occurred among children with 
>5 gpELISA units/mL. A FAMA titer >1:4 at 16 weeks post­
vaccination also correlates with protection against disease (82). 
However, neither o f these antibody tests is available commer­
cially. The relationship between the antibody level measured 
at other intervals postvaccination, especially immediately prior 
to exposure and breakthrough disease has not been studied. 
No correlates o f protection have been evaluated for adults.
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Vaccine Efficacy and Vaccine 
Effectiveness
One-Dose Regimen 
Prelicensure Efficacy
In prelicensure studies carried out among children aged
12 months—14 years, the protective efficacy o f single-antigen 
varicella vaccine varied, depending on the amount o f live 
virus administered per dose, the exposure setting (community 
or household), and the quality and length o f the clinical fol­
low-up. The majority o f the prelicensure studies reported effi­
cacy o f 1 dose o f varicella vaccine within the range o f 
70% —90% against any clinical disease and 95% against severe 
disease for 7—10 years after vaccination (81,101,102). A ran­
domized placebo-controlled efficacy trial was conducted 
among children aged 12 months—14 years, but the formula­
tion differed from that o f the current vaccine (17,000 PFUs 
per dose (103,104), with follow-up of children through 7 years 
postvaccination (105). Reported efficacy was 100% at 1 year 
and 98% at 2 years after vaccination, and 100% and 92%, 
respectively, after exposures to VZV that occurred in the house­
hold. Although a randomized control study was not conducted 
for adults, the efficacy o f single-antigen varicella vaccine was 
determined by evaluation o f protection when adult vaccine 
recipients were exposed to varicella in the household. On the 
basis o f the reported historical attack rate o f 87% for natural 
varicella after household exposure among unvaccinated chil­
dren, estimated efficacy among adults was approximately 80% 
(79). The attack rate o f unvaccinated adults exposed in house­
holds was not studied.
Postlicensure Efficacy and Effectiveness
Prevention o f AH Varicella Disease
Postlicensure studies have assessed the effectiveness^ o f the 
single-antigen varicella vaccine under field conditions in child 
care, school, household, and community settings using mul­
tiple methods. Effectiveness frequently has been estimated 
against all varicella and also against moderate and severe vari­
cella (defined in different ways). Outbreak investigations 
have assessed effectiveness against clinically defined varicella. 
The majority o f these investigations have demonstrated vac­
cine effectiveness for prevention o f varicella in the same 
range described in prelicensure trials (70%—90%) (3—6,106— 
113), with some lower (44%, 56%) (114,115) and some higher 
(100% in one o f two schools investigated) estimates (107). A
^ In this report, effectiveness refers to the extent to which a specific intervention, 
w hen deployed in the  field, does w hat it is in tended  to do for a defined 
population.
retrospective cohort study in 11 childcare centers demonstrated 
vaccine effectiveness o f 83% for prevention o f clinically diag­
nosed varicella (116). In a case-control study that measured 
vaccine effectiveness against laboratory-confirmed varicella in 
a pediatric office setting during 1997—2003, vaccine effec­
tiveness was 85% (CI = 78% —90%) during the first four years 
and 87% (CI = 81% —91%) for the entire study period 
(117,118). Finally, in a study o f household secondary attack 
rates, considered the most robust test o f vaccine performance 
because o f the intensity o f exposure, varicella vaccine was 79% 
(CI = 70% —85%) effective in preventing clinically defined 
varicella in exposed household contacts aged 12 months- 
14 years without a history o f varicella disease or vaccination 
(119). Postlicensure data on vaccine effectiveness against all 
disease have been summarized (Table 5).
In a randomized clinical trial conducted postlicensure that 
compared the efficacy o f 1 dose o f varicella vaccine with that 
o f 2 doses, the estimated vaccine efficacy for 1 dose for a 
10-year observation period was 94.4% (CI = 92.9% -95.7% ) 
(85; Table 3). In the same study, the efficacy o f 1 dose of 
vaccine in preventing varicella after household exposure for 
10 years was 90.2% (CI = 83.7% -96.7% ) (Table 4). This 
study did not use placebo controls and used historic data for 
attack rates in unvaccinated children to calculate vaccine 
efficacy.
Prevention of Moderate and Severe Varicella
Postlicensure studies assessing vaccine performance in 
preventing moderate and severe varicella have consistently 
demonstrated high effectiveness. Definitions for disease 
severity have varied among studies. Certain studies have used 
a defined scale o f illness that included the number o f skin 
lesions, fever, complications, and investigator assessment of 
illness severity, and others have used only the number o f 
skin lesions, reported complications, or hospitalizations.
T A B LE  5. S u m m a ry  o f p o s tlic e n s u re  d a ta  on  e ffe c tiv e n es s  o f 
s in g le -a n t ig e n  v a r ic e l la  v a c c in e  a g a in s t  d is e a s e  a m o n g  
ch ild ren  a g ed  12 m o n th s -1 4  years  —  U nited  S ta tes , 1 9 9 6 -2 0 0 4
Against moderate
Against all and severe
disease No. disease* No.
(%) estimates (%) estimates
<70 2 <70 0
70-79 4 70-79 0
80-89 13 80-89 1
>90 1 >90 16
* Definitions of severity differed among studies. Typically, cases were 
considered to be moderate for persons who had either 50-500 or 250­
500 lesions and severe for persons who had >500 lesions or who either 
were hospitalized or had a serious complication (e.g., skin or soft tissue 
infections). Two early studies defined severe disease as having >200 or 
>250 lesions. In another study, severity of disease was defined according 
to a modified disease severity score from the clinical trials.
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Moderate varicella typically has been defined as either 50­
500 or 250-500 lesions, and severe varicella has been defined 
as >500 lesions or any hospitalization or complication. In the 
randomized postlicensure clinical trial, severe varicella was 
defined as >300 lesions and fever o f >102°F (38.9°C), oral 
equivalent. Regardless o f different definitions, multiple stud­
ies have demonstrated that single-antigen varicella vaccine 
was >95% effective in preventing combined moderate and 
severe disease (3—6,85,106,107,109—113,115—119); one study 
demonstrated effectiveness o f 86% (114). Effectiveness was 
100% against severe disease when measured separately 
(6,85,109,111,117,119). Postlicensure data on vaccine effec­
tiveness against moderate and severe varicella have been 
summarized (Table 5).
Two-Dose Regimen
In a randomized clinical trial o f single-antigen varicella vac­
cine that compared the efficacy o f 1 dose with that o f 2 doses 
administered 3 months apart, the estimated vaccine efficacy 
o f 2 doses for a 10-year observation period was 98.3%  
(CI = 97.3% -99.0% ), which was significantly higher than 
efficacy after 1 dose (p<0.001) (85; Table 5). The 2-dose regi­
men also was 100% efficacious against severe varicella. In the 
same study, the efficacy o f 2 doses o f single-antigen varicella 
vaccine in preventing disease after household exposure over
10 years was 96.4% (CI = 92.4% -100% ), not significantly 
different from 1 dose (90.2%) (p = 0.112) (Table 4). How­
ever, the number o f cases involving household exposure was 
limited.
Formal studies to evaluate the clinical efficacy o f the com­
bination M MRV vaccine have not been performed. Efficacy 
o f the individual components was established previously in 
clinical studies with the single-antigen vaccines.
Breakthrough Disease
Breakthrough disease is defined as a case o f infection with 
wild-type VZV occurring >42 days after vaccination. In clini­
cal trials, varicella disease was substantially less severe among 
vaccinated persons than among unvaccinated persons, who 
usually have fever and several hundred vesicular lesions (120). 
In cases o f breakthrough disease, the median number o f skin 
lesions is com m only <50 (9 9 ,1 2 1 —123). In addition, 
compared with unvaccinated persons, vaccine recipients have 
had fewer vesicular lesions (lesions more commonly are atypi­
cal, with papules that do not progress to vesicles), shorter 
duration of illness, and lower incidence o f fever.
Multiple postlicensure investigations also have demonstrated 
that the majority o f breakthrough varicella cases are signifi­
cantly milder than cases among unvaccinated children (p<0.05) 
(3,5,107—114,116—118,124). However, approximately 25% - 
30% of breakthrough cases are not mild, with clinical features 
more similar to those in unvaccinated children (124). Since 
1999, when varicella deaths became nationally notifiable, two 
deaths from breakthrough varicella disease have been reported 
to C D C ; one of a girl aged 9 years with a history o f asthma 
who was receiving steroids when she had the breakthrough 
infection, and the other o f a girl aged 7 years with a history of 
malignant ependymoma who also was under steroid therapy 
at the time o f her death (CD C, unpublished data, 2006).
One-Dose Regimen
In clinical trials, 1,114 children aged 1-12 years received
1 dose o f single-antigen varicella vaccine containing 2,900­
9,000 PFUs of attenuated virus per dose and were actively 
followed for up to 10 years postvaccination (79). Among a 
subset o f 95 vaccine recipients with household exposure to 
varicella, eight (8%) reported a mild form o f varicella (10-34 
lesions).
In a randomized clinical trial that compared the efficacy of
1 dose o f vaccine to that o f 2 doses during a 10-year observa­
tion period, the cumulative rate o f breakthrough varicella 
among children who received 1 dose was 7.3% (85). Break­
through cases occurred annually in 0.2% -2.3%  o f recipients 
o f 1 dose o f vaccine. Cases occurred throughout the observa­
tion period, but the majority were reported 2-5 years after 
vaccination (Figure 4). O f 57 children with breakthrough cases,
13 (23%) had >50 lesions.
In cross-sectional studies, the attack rate for breakthrough 
disease has ranged between 11% and 17% (and as high as 
40% in certain classrooms) in outbreak investigations (3 ) and 
15% in household settings (119).
F IG U R E  4. C u m u la tiv e  b re a k th ro u g h  ra tes* fo r 1 an d  2 d oses  
o f  s in g le -a n tig e n  v a r ic e lla  v a c c in e  a m o n g  c h ild re n  a g e d  
1 2  m o n th s -1 2  y e a rs , by  n u m b e r o f y e a rs  a fte r v a c c in a tio n  —  
U n ite d  S ta te s , 1 9 9 3 -2 0 0 3
Year
Source: Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of 
healthy children who received one or two injections of varicella vaccine. 
Pediatr Infect Dis J 2004;23:132-7.
* Per 100 person-years at risk.
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Two-Dose Regimen 
Data Among Children
In a randomized clinical trial that compared the efficacy o f
1 dose o f vaccine with that o f 2 doses, the cumulative rate of 
breakthrough varicella during a 10-year observation period 
was 3.3-fold lower among children who received 2 doses than 
that among children who received 1 dose (2.2% and 7.3, 
respectively; p<0.001) (85). Breakthrough cases occurred 
occasionally in 0.8%  o f 2-dose vaccine recipients. The 
majority o f cases o f breakthrough disease occurred 2-5 years 
after vaccination; no cases were reported 7-10  years after vac­
cination (Figure 4). O f 16 children with breakthrough cases, 
three (19%) had >50 lesions. The proportion of children with 
>50 lesions did not differ between the 1-dose and 2-dose 
regimens (p = 0.5).
Breakthrough Infections Among Adolescents 
and Adults
In postlicensure studies o f adolescents and adults who 
received 2 doses, 40 (9%) cases o f breakthrough varicella 
occurred among 461 vaccine recipients who were followed 
for 8 weeks-11.8 years (mean: 3.3 years) after vaccination 
(95), and 12 (10%) cases occurred among 120 vaccine recipi­
ents who were followed for 1 month-20.6 years (mean: 4.6 
years) (94). One prelicensure study o f persons who had 
received 2 doses o f vaccine reported that 12 (8%) breakthrough 
cases had occurred among 152 vaccine recipients who were 
followed for 5-66 months (mean: 30 months) postvaccina­
tion (93).
Contagiousness
Prelicensure clinical trials reported the rate o f disease trans­
mission from vaccinated persons with varicella cases to their 
vaccinated siblings. In 10 trials that were conducted during
1981-1989, breakthrough infections occurred in 114 (5.3%) 
of 2,163 vaccinated children during the 1-8 year follow-up 
period of active surveillance, and secondary transmission oc­
curred to 11 (12.2%) of their 90 vaccinated siblings (121). 
Illness was mild in both index and secondary case-patients. 
Household transmission from a vaccinated child with break­
through disease to a susceptible adult (one o f whom died) 
have been reported (CD C, unpublished data, 2006). One 
study examined secondary attack rates from vaccinated and 
unvaccinated persons with varicella to both vaccinated and 
unvaccinated households contacts aged 12 months-14 years 
(119). This study demonstrated that vaccinated persons with 
varicella with <50 lesions were only one third as contagious as 
unvaccinated persons with varicella. However, vaccinated
persons with varicella who had >50 lesions were as contagious 
as unvaccinated persons with varicella (119). Vaccinated per­
sons with varicella tend to have milder disease, and, although 
they are less contagious than unvaccinated persons with vari­
cella, they might not receive a diagnosis and be isolated. As a 
result, they might have more opportunities to infect others in 
community settings, thereby further contributing to VZV 
transmission. Vaccinated persons with varicella also have been 
index case-patients in varicella outbreaks (3,4,115).
Risk Factors for Vaccine Failure
Potential risk factors for vaccine failure have been identified 
in studies o f vaccine effectiveness during outbreak investiga­
tions and other specially designed studies (5,108—110,113— 
115,118,125). In outbreak investigations, the low number of 
cases limits the ability o f researchers to conduct multivariate 
analyses and examine the independent effect o f each risk fac­
tor for vaccine failure. An increased risk for breakthrough dis­
ease has been noted with decreasing age at vaccination, with a 
threefold increase in breakthrough disease risk for children 
vaccinated at age <14 months (110), an increase o f twofold in 
one study and nearly fourfold in another for children vacci­
nated at age <16 months (108,115), and a ninefold increase 
for children vaccinated at age <19 months (113). Other out­
break investigations have demonstrated that time since vacci­
nation (variably defined as >3, >5, or >5 years) was associated 
with an increased risk for breakthrough disease (relative risk 
[RR] = 2.6, 6.7, and 2.6, respectively) (5,114,115). However, 
age at vaccination and time since vaccination are highly cor­
related, and their independent association with the risk for 
breakthrough disease has been assessed in only one outbreak 
investigation (113). A retrospective cohort study that adjusted 
for other potential risk factors demonstrated an increased risk 
for breakthrough disease for children vaccinated at age <15 
months (adjusted relative risk [aRR] = 1.4; CI = 1.1%—1.9%)
(125). A case-control study demonstrated that the effective­
ness o f vaccine in the first year after vaccination was signifi­
cantly lower (73%) among children vaccinated at age <15 
months than it was among children vaccinated at age >15 
months (99%) (p = 0.01) (118). However, the difference in 
the overall effectiveness between children vaccinated at these 
ages was not statistically significant for subsequent years 
(8 years o f follow-up) (81% and 88%, respectively; p = 0.17). 
Active surveillance data collected during 1995—2004 from a 
sentinel population o f 350,000 persons were analyzed to 
determine whether the severity and annual incidence o f break­
through varicella cases increased with time since vaccination
(126). Children vaccinated >5 years previously were 2.6 times 
more likely to have moderate and severe breakthrough
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varicella than those vaccinated <5 years previously (p = 0.016). 
The annual rates o f breakthrough varicella among children 
aged 12 months-12 years increased significantly with time 
since vaccination after adjusting for the effects o f age at infec­
tion, age at vaccination, and year o f infection (p<0.01).
Multiple other studies that examined possible reasons for 
lower vaccine effectiveness did not find age at vaccination 
(3—5,111,114) or time since vaccination (3,110,111) to be 
associated with vaccine failure. An ongoing study is examin­
ing these factors and risk for vaccine failure (127). After 8 years 
o f active follow-up o f7,449 children vaccinated at age 12-23 
months, results do not indicate an increased risk for break­
through disease among children vaccinated at age 12-14 
months compared with those vaccinated at age 15-23 months. 
Moreover, a test for trend revealed no change in the rate of 
reported breakthrough disease for each additional month of 
age at vaccination (127).
Two outbreak investigations noted an increased risk for 
breakthrough disease in children with asthma and eczema 
(109,113). In these investigations, the use o f steroids to treat 
asthma or eczema was not studied. Steroids have been associ­
ated previously with severe varicella in unvaccinated persons 
(128—130). Only one retrospective cohort study controlled 
simultaneously for the effect o f multiple risk factors, includ­
ing the use o f steroids, and this study demonstrated no asso­
ciation of risk for breakthrough disease with asthma or eczema 
(125). However, this study documented an increased risk for 
breakthrough disease if the child had received a prescription 
of oral steroids (considered a proxy for taking oral steroids 
when exposed to varicella) within 3 months o f breakthrough 
disease (adjusted RR [aRR] = 2.4; CI = 1.3%—4.4%) and when 
varicella vaccination was administered within 28 days o f M M R 
vaccine (aRR = 3.1; CI = 1.5%—6.4%).
Evidence of Immunity
ACIP has approved criteria for evidence o f immunity to 
varicella (Box). Only doses ofvaricella vaccines for which writ­
ten documentation o f the date o f administration is presented 
should be considered valid. Neither a self-reported dose nor a 
history o f vaccination provided by a parent is, by itself, con­
sidered adequate evidence o f immunity. Persons who lack docu­
mentation o f adequate vaccination or other evidence of 
immunity should be vaccinated.
Historically, self-reporting o f varicella disease by adults or 
by parents for their children has been considered valid evi­
dence o f immunity. The predictive value o f a self-reported 
positive disease history was extremely high in adults in the 
prevaccine era although data on positive predictive value are 
lacking in parental reports regarding their children (131—133).
B O X . E v id e n c e  o f im m u n ity  to  v a ric e lla
Evidence o f immunity to varicella includes any o f the
following:
• documentation of age-appropriate vaccination with a 
varicella vaccine
—  preschool-aged children (i.e., aged >12 months):
1 dose
—  school-aged children, adolescents, and adults:
2 doses*
• laboratory evidence o f immunity^ or laboratory confir­
mation o f disease
• birth in the United States before 1980§
• diagnosis or verification of a history of varicella disease by 
a health-care provider^
• diagnosis or verification o f a history o f herpes zoster by 
a health-care provider
•  For children who received their first dose at age <13 years and for w hom
the interval betw een the  2 doses was >28 days, the  second dose is 
considered valid.
 ̂ Com m ercial assays can be used to assess disease-induced im m unity, but 
they lack sensitivity to always detect vaccine-induced im m unity  (i.e., 
they m ight yield false-negative results).
§ For health-care personnel, pregnant wom en, and im m unocom prom ised 
persons, b ir th  before 1 9 8 0  shou ld  n o t be considered  evidence o f  
im m unity.
^ Verification o f  history or diagnosis o f  typical disease can be provided by 
any health-care provider (e.g., school or occupational clinic nurse, nurse 
practitioner, physician assistant, or physician). For persons reporting a 
history of, or reporting with, atypical or m ild cases, assessment by a 
physician or their designee is recom m ended, and one o f  the  following 
should be sought: 1 ) an epidemiologic link to a typical varicella case to a 
laboratory-confirm ed case or 2) evidence o f  laboratory confirm ation, if 
it was perform ed at the tim e o f  acute disease. W hen  such docum entation 
is lacking, persons should n o t be considered as having a valid history o f 
disease because other diseases m ight m im ic m ild atypical varicella.
As disease incidence decreases and the proportion o f vacci­
nated persons with varicella having mild cases increases, vari­
cella will be less readily recognized clinically. A recent study 
demonstrated that only 75% of unvaccinated children aged 
12 months—4 years who reported a positive history o f 
varicella were in fact immune (confirmed by serological test­
ing), compared with 89% of children aged 5—9 years and
10—14 years (134). To limit the number o f false-positive reports 
and ensure immunity, ACIP recommends that evidence of 
immunity should be either a diagnosis o f varicella by a health­
care provider or a health-care provider verification of a his­
tory o f disease rather than parental or self-reporting. The 
above-cited study demonstrated that 99% o f persons aged 
15—19 years and 100% o f those aged 20—29 years who 
reported a history o f varicella were immune (134). Because 
serologic evidence ofV ZV  infection has been documented in 
96%—97% of U.S.-born adults aged 20—29 years and in 97%— 
99% of adults aged >30 years tested during 1998—1999 (12), 
U.S. birth before 1980 is considered evidence o f immunity 
except for health-care personnel (HCP), pregnant women, and
Vol. 56 / RR-4 Recommendations and Reports 17
immunocomprised persons. For these three groups, certainty 
regarding immunity is desirable because o f the possibility o f 
nosocomial transmission to high-risk patients; transmission 
of the virus to the fetus, which might result in congenital 
varicella syndrome; and the possibility o f severe disease. Post­
vaccination serologic testing to verify an immune response to 
varicella vaccine is not routinely recommended because avail­
able commercial assays lack sensitivity in detecting vaccine- 
induced immunity and might give false negative results.
Simultaneous Administration 
of Vaccines
Single-antigen varicella vaccine is well-tolerated and effec­
tive in healthy children aged >12 months when administered 
simultaneously with M M R vaccine either at separate sites and 
with separate syringes or separately >4 weeks apart. The num­
ber and types o f adverse events occurring in children who have 
received VARIVAX and MMRII concurrently have not dif­
fered from those in children who have been administered the 
vaccines at different visits (79,135). Data concerning the 
effect o f simultaneous administration o f VARIVAX with vac­
cines containing various combinations o f MMR, diphtheria 
and tetanus toxoids and pertussis (DTP), and Haemophilus 
influenzae type b (Hib) have not been published (79). A ran­
domized study of 694 subjects determined that the immune 
response to M M R, varicella, and Hib vaccines administered 
concurrently with a fourth dose o f pneumococal conjugate 
vaccine (PCV7) was not inferior to that o f those vaccines when 
administered without PCV7; the percentage o f subjects who 
seroconverted was >90% for all antigens for both groups (136).
Concomitant administration o f the combination MMRV 
vaccine with other vaccines also has been assessed. In a clini­
cal trial involving 1,913 healthy children aged 12-15 months, 
three groups were compared (137). One group received con­
comitantly administered (at separate sites) M MRV vaccine, 
Diphtheria and Tetanus Toxoids and Acellular Pertussis 
Vaccine Absorbed (DTaP), Hib conjugate (meningococcal 
protein conjugate) vaccine, and hepatitis B (recombinant) 
(Hep B) vaccine. The second group received MMRV vaccine 
at the initial visit, followed by DTaP, Hib, and Hep B vac­
cines administered concomitantly 6 weeks later. The third 
group received M M R and varicella vaccines concomitantly 
followed 6 weeks later by DTaP, Hib, and Hep B vaccines. 
Seroconversion rates and antibody titers were comparable for 
the measles, mumps, rubella, and varicella components for 
the first two groups. No immunologic data were reported for 
the third group. The Hib and Hep B seroconversion rates for the 
two groups that received those vaccines also were comparable.
Data are absent or limited for the concomitant use of MMRV 
vaccine with inactivated polio, pneumococal conjugate, 
influenza, and hepatitis A vaccines. Simultaneous administra­
tion o f the majority o f widely used live and inactivated vac­
cines has produced seroconversion rates and rates o f adverse 
reactions similar to those observed when the vaccines are 
administered separately. Therefore, single-antigen and com­
bination MMRV vaccines may be administered simultaneously 
with other vaccines recommended for children aged 12-15 
months and those aged 4-6  years. Simultaneous administra­
tion is particularly important when health-care providers 
anticipate that, because o f certain factors (e.g., previously 
missed vaccination opportunities), a child might not return 
for subsequent vaccination.
Economic Analysis of Vaccination
A cost-effectiveness analysis was performed before initia­
tion o f the varicella vaccination program in the United States 
(138). The results o f the study indicated a savings o f $5.40 
for each dollar spent on routine vaccination of preschool-aged 
children when direct and indirect costs were considered. When 
only direct medical costs were considered, the benefit-cost ratio 
was 0.9:1.0. Benefit-cost ratios were only slightly lower when 
lower estimates o f the short- and long-term effectiveness of 
the vaccine were used.
A recent analysis was performed that used current estimates 
o f morbidity and mortality (20,28,33) and current direct and 
indirect costs (ACIP, unpublished presentation, 2006). The 
model considered that the second dose will reduce varicella 
disease residual after the first dose by 79%. From a societal 
perspective, both 1-dose and 2-dose vaccination programs are 
cost saving compared with no program. The vaccine program 
cost was estimated at $320 million for 1 dose and $538 mil­
lion for 2 doses. The savings from varicella disease prevented 
were estimated at approximately $1.3 billion for the 1-dose 
program and approximately $1.4 billion for the 2-dose pro­
gram. Compared with the 1-dose program, the incremental 
cost for the second dose was estimated to be $96,000 per qual­
ity-adjusted life year (QALY) saved. I f  benefits from prevent­
ing group A streptococcus infections and H Z  among 
vaccinated persons are added, incremental costs per QALY 
saved are $91,000 and $17,000, respectively. Because o f the 
uncertainty o f the modeled predictions o f an increase in HZ 
among persons with a history o f varicella and the fact that no 
consistent trends demonstrate an increase in H Z attributable 
to the varicella vaccination program in the United States, HZ 
among persons with a history o f varicella was not included in 
the model.
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Storage, Handling, 
and Transportation 
of Varicella Vaccines
Single-antigen varicella and combination M MRV vaccines 
have similar but not identical distribution, handling, and stor­
age requirements (79,80). For potency to be maintained, the 
lyophilized varicella vaccines must be stored frozen at an aver­
age temperature o f 5°F (-15°C) or colder. Household freezers 
manufactured since the mid-1980s are designed to maintain 
temperatures from -4°F (-20°C) to 5°F (-15°C). When tested, 
VARIVAX has remained stable in frost-free freezers. Freezers 
that reliably maintain an average temperature o f <5°F (<-15°C) 
and that have a separate sealed freezer door are acceptable for 
storing VARIVAX and ProQuad. Health-care providers may 
use stand-alone freezers or the freezer compartment o f refrig­
erator-freezer combinations, provided that the freezer com­
partment has its own separate, sealed, and insulated exterior 
door. Units with an internal freezer door are not acceptable. 
Temperatures should be documented at the beginning and 
end of each day. Providers should document the required tem­
perature in a newly purchased unit for a minimum of 1 week 
before using it to store vaccine and routinely thereafter. When 
varicella vaccines are stored in the freezer compartment o f a 
combined refrigerator-freezer, temperatures in both compart­
ments should be monitored carefully. Setting the thermostat 
low enough for storage o f varicella-containing vaccines might 
inadvertently expose refrigerated vaccines to freezing tempera­
tures. Refrigerators with ice compartments that either are not 
tightly enclosed or are enclosed with unsealed, uninsulated 
doors (e.g., small, dormitory-style refrigerators) are not 
acceptable for the storage o f varicella vaccines.
Diluent should be stored separately either at room tempera­
ture or in the refrigerator. Vaccines should be reconstituted 
according to the directions in the package insert and only with 
the diluent supplied with the vaccine, which does not contain 
preservative or other antiviral substances that could inactivate 
the vaccine virus. Once reconstituted, vaccine should be used 
immediately to minimize loss o f potency. Vaccine should be 
discarded if not used within 30 minutes after reconstitution.
Handling and Transportation 
of Varicella Vaccines 
Within Off-Site Clinics
When an immunization session is being held at a site dis­
tant from the freezer in which the vaccine is stored, the num­
ber o f vaccine vials needed for the immunization session should 
be packed in either a vaccine shipping container (as received 
from the manufacturer) or in an insulated cooler, with an
adequate quantity o f dry ice (i.e., a minimum of 6 lbs per 
box) to preserve potency. When placed in a suitable container, 
dry ice will maintain a temperature o f <5°F (<-15°C). Dry ice 
should remain in the container upon arrival at the clinic site. 
If  no dry ice remains when the container is opened at the 
receiving site, the manufacturer (Merck and Company, Inc.) 
should be contacted for guidance (telephone: 1-800-982­
7482). If dry ice is available at the receiving site, it may be 
used to store vaccine. Thermometers or temperature indica­
tors cannot be used in a container with dry ice. Diluent should 
not be transported on dry ice.
I f dry ice is not available, only single-antigen varicella vac­
cine may be transported, with frozen packs to keep the tem­
peratures between 3 6 °F - 4 6 °F  (2 °C - 8 °C ) .  Transport 
temperatures should be monitored, and a temperature indi­
cator or thermometer should be placed in the container and 
checked on arrival. The container should be kept closed as 
much as possible during the immunization session; tempera­
tures should be checked and recorded hourly. If the tempera­
ture rem ains between 3 6 °F - 4 6 °F  (2 °C - 8 °C ) ,  the 
single-antigen varicella vaccine may be used for up to 72 hours 
after its removal from the freezer. The date and time should 
be marked on the vaccine vial. Single-antigen varicella vac­
cine stored at refrigerated temperatures for any period of time 
may not be refrozen for future use.
Transportation and storage o f combination MMRV vaccine 
at temperatures between 36°F-46°F (2°C-8°C) is not permis­
sible for any length of time. In contrast to single-antigen vari­
cella vaccine, combination MMRV vaccine must be maintained 
at temperatures o f <5°F (<-15°C) until the time of reconstitu­
tion and administration. This difference in vaccine storage tem­
peratures must be considered when planning off-site clinics. 
For this reason, transportation of MMRV vaccine to off-site 
clinics is not advised. If any concerns arise regarding the storage 
of single-antigen varicella or combination MMRV vaccines, the 
manufacturer should be contacted for guidance.
Minimizing Wastage of Vaccine
Vaccine wastage can be minimized by accurately determin­
ing the number o f doses needed for a given patient popula­
tion. To ensure maximal vaccine potency, smaller shipments 
o f vaccine should be ordered more frequently (preferably at 
least once every 3 months). Single-antigen varicella vaccine 
should not be distributed to providers who do not have the 
capacity to store it properly in a freezer until it is used. Trans­
portation of varicella vaccine should be kept to a minimum to 
prevent loss o f potency. Off-site clinic sites should receive only 
such amounts o f vaccine as they can use within a short time 
(72 hours if storing single-antigen varicella vaccine at refrig­
erated temperatures).
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Adverse Events After Vaccination
Because adverse events after vaccination might continue to 
be caused by wild-type VZV even as varicella disease declines, 
health-care providers should obtain event-appropriate clini­
cal specimens (e.g., cerebrospinal fluid for encephalitis, bron­
chial lavage or lung biopsy for pneumonia) for laboratory 
evaluation, including strain identification. Information regard­
ing strain identification is available from Merck’s VZV Iden­
tification Program (telephone: 1-800-652-6372) or from 
C D C ’s National Varicella Reference Laboratory (telephone: 
404-639-0066; e-mail: vzvlab@cdc.gov) or at http://www. 
cdc.gov/nip/diseases/varicella/surv/default.htm. Commercial 
laboratories do not have the capability for strain identification.
The National Vaccine Injury Act o f 1986 requires physi­
cians and other health-care providers who administer vaccines 
to maintain permanent immunization records and to report 
occurrences o f adverse events for selected vaccines, including 
varicella vaccines. Serious adverse events (i.e., all events 
requiring medical attention) suspected to have been caused 
by varicella vaccines should be reported to the Vaccine 
Adverse Event Reporting System (VAERS). Forms and instruc­
tions are available at h ttp s://secu re .vaers.o rg / 
vaersDataEntryintro.htm, in the FD A  Drug Bulletin at 
http://www.fda.gov/medwatch, or from the 24-hour VAERS 
information recording at 1-800 822-7967.
Prelicensure
Single-Antigen Varicella Vaccine
Single-antigen varicella vaccine was well-tolerated when 
administered to >11,000 healthy children, adolescents, and 
adults during prelicensure clinical trials. In a double-blind, 
placebo-controlled study among 914 susceptible healthy chil­
dren aged 12 months-14 years, the only statistically signifi­
cant (p<0.05) adverse events reported that were more common 
among vaccine recipients than among placebo recipients were 
pain and redness at the injection site (103). This study also 
described the presence o f unspecific rash among 2% of pla­
cebo and 4% of vaccine recipients occurring within 43 days 
o f vaccination. O f the 28 reported rashes, 10 (36%) were 
examined by a physician; among those that were examined, 
four o f the seven noninjection site rashes in vaccine recipients 
were judged to be varicella-like, compared with none o f the 
rashes in the placebo recipients.
In a study comparing the safety o f 1 dose o f single-antigen 
varicella vaccine with that o f 2 doses administered 3 months 
apart, no serious adverse events related to vaccination were 
reported among approximately 2,000 healthy subjects aged 
12 months-12 years who were followed for 42 days after
each injection. The 2-dose vaccine regimen was generally well- 
tolerated, and its safety profile was comparable to that o f the 
1-dose regimen. Incidence o f injection site complaints 
observed <3 days after vaccination was slightly higher after 
dose 2 (25.4%) than after dose 1 (21.7%). Incidence o f sys­
temic clinical complaints was lower after dose 2; fever inci­
dence from days 7—21 was 7% after dose 1 and 4% after dose
2 (p = 0.009), and varicelliform rash incidence after dose 1 
was 3%, compared with 1% after dose 2 (p = 0.008), with 
peak occurrence 8—21 days after vaccination (139).
In uncontrolled trials o f persons aged >13 years , approxi­
mately 1,600 vaccine recipients who received 1 dose o f single­
antigen varicella vaccine and 955 who received 2 doses of 
vaccine were monitored for 42 days for adverse events (79). 
After the first and second doses, 24.4% and 32.5% o f vaccine 
recipients, respectively, had complaints regarding the injec­
tion site. Varicella-like rash at the injection site occurred in 
3% of vaccine recipients after the first injection and in 1% 
after the second. A nonlocalized rash occurred in 5.5% of 
vaccine recipients after the first injection and in 0.9% o f vac­
cine recipients after the second, at a peak of 7—21 and 0—23 
days postvaccination, respectively.
Combination MMRV Vaccine
In clinical trials, combination MMRV vaccine was admin­
istered to 4,497 children aged 12—23 months without con­
comitant administration with other vaccines (80). The safety 
profile of the first dose was compared with the safety o f MMRII 
vaccine and VARIVAX administered concomitantly at sepa­
rate injection sites. The follow-up period was 42 days post­
vaccination. Systemic vaccine-related adverse events were 
reported at a statistically significantly greater rate in persons 
who received M MRV vaccine than in persons who received 
the two vaccines administered concomitantly at separate 
injection sites: fever (>102°F [>38.9°C] oral equivalent), 
(21.5% and 14.9%, respectively), and measles-like rash (3.0% 
and 2.1%, respectively). Both fever and measles-like rash usu­
ally occurred within 5—12 days after the vaccination, were of 
short duration, and resolved with no long-term sequelae. Pain, 
tenderness, and soreness at the injection site were reported at 
a statistically significantly lower rate in persons who received 
the combination MMRV vaccine (22.0%) than in those who 
received MMRII and VARIVAX vaccines (26.7%). Rash at 
the injection site was more frequent among recipients o f 1-dose 
MMRV vaccine (2.3%) than among recipients o f the two vac­
cines administered separately as first doses (1.5%). A study 
that also com pared use o f M M RV  with M M R II and 
VARIVAX administered as a first dose demonstrated similar 
results (90). During days 5—12, children in the group that 
received M MRV had higher rates o f elevated temperatures
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than those in the group that received MMRII and VARIVAX 
(27.7% and 18.7%, respectively; p = 0.034).
To demonstrate that M MRV vaccine could be administered 
as a second dose, a study was conducted involving 799 chil­
dren aged 4-6  years who had received primary doses o f MMRII 
and VARIVAX vaccines, either concomitantly or not, at age 
>12 months and >1 month before study enrollment (91). 
These children were vaccinated randomly (with MMRV and 
placebo, M M R and placebo, or M MRII and VARIVAX) and 
then monitored for safety. No serious vaccine-related adverse 
experiences were reported. Overall, the proportions o f sub­
jects with one or more adverse event were comparable among 
groups receiving M M RV, M M R II, and M M R II and 
VARIVAX. The group receiving MMRV vaccine had a statis­
tically significantly greater proportion o f subjects with 
erythema (p = 0.01) and swelling (p = 0.008) at the injection 
site 1-5 days after vaccination. Another study examined the 
safety o f 2 doses o f M MRV administered 3 months apart to 
480 children aged 12-23 months (90). The rate o f adverse 
events typically was lower after the second dose o f MMRV 
than after the first dose. The incidence o f varicella-like rashes 
was lower after a second dose o f M MRV than after concomi­
tant administration of MMRII and VARIVAX vaccines (0.0% 
and 1.9%, respectively; p = 0.01).
Postlicensure
During March 1, 1995-December 31, 2005, a total o f 47.7 
million doses o f varicella vaccine were distributed in the United 
States, and 25,306 adverse events that occurred after varicella 
vaccine administration were reported to VAERS, 1,276 (5%) 
of which were classified as serious. The overall adverse event 
reporting rate was 52.7 cases per 100,000 doses distributed. 
The rate o f reporting o f serious adverse events was 2.6 per
100,000 doses distributed. H alf o f all adverse events reported 
occurred among children aged 12-23 months (VAERS, 
unpublished data, 2006).
Not all adverse events that occur after vaccination are 
reported, and many reports describe events that might have 
been caused by confounding or unrelated factors (e.g., medi­
cations and other diseases). Because varicella disease contin­
ues to occur, wild-type virus might account for certain reported 
events. For serious adverse events for which background inci­
dence data are known, VAERS reporting rates are lower than 
expected after natural varicella or than background rates of 
disease in the community. Inherent limitations o f passive safety 
surveillance impede comparing adverse event rates after vac­
cination reported to VAERS with those from complications 
after natural disease. Nevertheless, the magnitude o f these dif­
ferences suggests that serious adverse events occur at a
substantially lower rate after vaccination than after natural 
disease. This assumption is corroborated by the substantial 
decline in the number o f severe complications, hospitaliza­
tions, and deaths related to varicella that have been reported 
since implementation o f the varicella vaccination program 
(22,23,28).
Similar to the prelicensure experience, postlicensure safety 
surveillance data after administration of single-antigen vari­
cella vaccine indicated that rash, fever, and injection-site reac­
tions were the most frequently reported adverse events 
(140,141). Using these reports from passive surveillance of 
adverse events during the first 4 years o f the vaccination pro­
gram, when wild-type VZV was still circulating widely, poly­
merase chain reaction (PCR) analysis confirmed that the 
majority o f rash events occurring within 42 days o f vaccina­
tion were caused primarily by wild-type varicella-zoster virus. 
Rashes from the wild-type virus occurred a median of 8 days 
after vaccination (range: 1-24 days), whereas rashes from the 
vaccine strain occurred a median of 21 days after vaccination 
(range: 5-42 days) (140).
As part o f postmarketing evaluation o f the short-term safety 
o f VARIVAX, 89,753 vaccinated adults and children were 
identified from automated clinical databases o f hospitals, 
emergency room visits, and clinic visits during April 1995- 
December 1996 (56). Out o f all potential adverse events iden­
tified, no consistent time association or clustering o f any events 
was noted during the exposure follow-up period. No cases o f 
ataxia or encephalitis were identified after receipt o f varicella 
vaccine in this group of vaccine recipients. In the prevaccine 
era, among children aged <15 years, acute cerebellar ataxia 
was estimated to occur at a rate o f one in 4,000 varicella cases, 
and varicella encephalitis without ataxia was estimated to 
occur at one in 33,000 varicella cases (142).
Severe complications that are laboratory-confirmed to be 
caused by vaccine virus strain are rare and include pneumonia 
(140), hepatitis (143), severe disseminated varicella infection 
(140,141,144,145), and secondary transmission from five 
vaccine recipients (140,146—148). Except for the secondary 
transm ission  cases, these cases all occurred in 
immunocompromised patients or in persons who had other 
serious medical conditions that were undiagnosed at the time 
of vaccination.
Although other serious adverse events have been reported, 
vaccine strain involvement was not laboratory-confirmed. 
Thrombocytopenia (140,141,149) and acute cerebellar ataxia 
(140,141,150) have been described as potentially associated 
with single-antigen varicella vaccine. Two children had acute 
hemiparesis diagnosed after varicella vaccination (one at 5 days 
and the other at 3 weeks) (151). In both cases, unilateral
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infarction o f the basal ganglia and internal capsule was noted; 
this distribution is consistent with varicella angiopathy. Urti­
caria after varicella vaccine has been associated with gelatin 
allergy (152). Recurrent papular urticaria has been reported 
to be potentially associated with varicella vaccination (153). 
However, available data regarding the potential adverse events 
after varicella vaccination are insufficient to determine a 
causal association. The quality o f reported information varies 
widely, and simultaneous administration with other vaccines 
(especially MMR) might confound attribution.
Herpes Zoster. Similar to wild-type VZV, vaccine virus can 
establish latent infection and subsequently reactivate, causing 
H Z disease in vaccine recipients. Before vaccine licensure, studies 
in children with leukemia had demonstrated a much lower rate 
o f H Z in vaccinated children compared with those (age and 
protocol matched) with previous varicella (54). Cases o f H Z in 
healthy vaccine recipients have been confirmed to be caused by 
both vaccine virus and wild-type virus, suggesting that certain 
H Z cases in vaccine recipients might result from antecedent 
natural varicella infection that might not have been detected by 
the patient or from infection after vaccination (140). A single 
case has been reported o f a child who received a diagnosis of 
neuroblastoma and had severe chronic zoster attributed to vac­
cine virus strain that with time became drug resistant (145). A 
large postlicensure safety study performed through surveys con­
ducted every 6 months and validated by medical chart review 
in the first 9 years o f a 15-year follow-up study of >7,000 en­
rolled children vaccinated with single-antigen varicella vaccine 
at age 12-24 months estimated H Z disease incidence to be 22 
per 100,000 person-years (CI = 13-37) as reported by parents 
(Steven Black, M D, Northern California Kaiser Permanente 
Medical Care Program, unpublished presentation, 2005). The 
incidence o f H Z was 30 per 100,000 person-years among 
healthy children aged 5-9 years (154) and 46 per 100,000 per­
son-years for those aged <14 years (64). However, these rates 
are drawn from different populations and based on different 
methodologies. In addition, a proportion of children in these 
age groups would not have experienced varicella disease; those 
rates are likely to underestimate rates in a cohort o f children all 
infected with wild-type VZV, making direct comparison 
difficult with a vaccinated cohort.
Transmission of Vaccine Virus
Results from prelicensure vaccine trials o f the single­
antigen varicella vaccine suggest that transmission o f varicella 
vaccine virus from healthy persons to susceptible contacts is 
rare. This risk was assessed in siblings o f healthy vaccinated 
children who themselves received placebo (103). Six (1%) of
439 placebo recipients seroconverted without rash; the vacci­
nated siblings o f these six children also did not develop rash. 
Serologic data suggested that three o f these six seroconverters 
received vaccine mistakenly in lieu o f their siblings. In a smaller 
study, immunocompromised siblings o f healthy children 
receiving varicella vaccine were evaluated clinically and by test­
ing for humoral or cell-mediated immune responses (155). 
No evidence was demonstrated o f vaccine virus transmission 
to any o f 30 immunocompromised siblings from 37 healthy 
children receiving varicella vaccine.
Accumulated data from postlicensure surveillance activities 
suggest that the risk for transmission of varicella vaccine virus 
from healthy persons to susceptible contacts is low. With >55 
million doses ofVARIVAX distributed since licensure, trans­
mission from immunocompetent persons after vaccination has 
been documented by PCR analysis from only five persons, 
resulting in six secondary infections, all o f  them mild 
(140,146—148). Three episodes involved transmission from 
healthy children aged 1 year to healthy household contacts, 
including a sibling aged 4 months, a father, and a pregnant 
mother. In the latter episode, the mother chose to terminate 
the pregnancy, but fetal tissue tested subsequently by PCR 
was negative for varicella vaccine virus (147). The children in 
these episodes had 2, 12, and 30 lesions, respectively. A fourth 
episode involved transmission from an immunocompetent 
adolescent who was a resident in an institution for chroni­
cally disabled children. The adolescent had >500 lesions after 
vaccination, and vaccine virus was transmitted to another 
immunocompetent resident o f the institution and to a health­
care worker, both o f whom had histories o f varicella (146). 
The fifth episode represented a tertiary spread from a healthy 
sibling contact o f a vaccinee with leukemia (148). Rashes for 
both healthy siblings were mild (i.e., 40 and 11 lesions, 
respectively), and vaccine virus was isolated from all three case- 
patients. The third sibling had rash 18 days after the onset of 
the secondary case-patient and 33 days after rash onset in the 
vaccinated leukemic child. In addition to these five episodes, 
one child has been reported to have transmitted vaccine virus 
from H Z that occurred 5 months after varicella vaccination;
2 weeks later, a mild varicella-like rash from which vaccine 
varicella virus was isolated occurred in the child’s vaccinated 
brother (156).
Although varicella vaccine is not recommended for chil­
dren with cellular immune deficiencies, the experience from 
prelicensure vaccine trials involving children with leukemia is 
instructive. Data from a study o f varicella vaccination in chil­
dren with leukemia indicated that varicella virus vaccine trans­
mission occurred in 15 (17%) o f 88 healthy, susceptible 
siblings o f leukemic vaccine recipients; the rash was mild in
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11 (73%) of the 15 infected siblings (148). The risk for trans­
mission was correlated with the number o f skin lesions in the 
immunocompromised vaccine recipients.
These data suggest that healthy, vaccinated persons have a 
minimal risk for transmitting vaccine virus to their contacts, 
particularly in the absence o f vaccine rash in the vaccine 
recipient. Vaccine recipients who have a vaccine-related rash, 
particu larly  H C P  and household contacts o f 
immunocompromised persons, should avoid contact with 
persons without evidence o f immunity who are at high risk 
for severe complications (see Health-Care Personnel)
Summary of Rationale for Varicella 
Vaccination
Varicella vaccine is an effective prevention tool for decreas­
ing the burden attributable to varicella disease and its compli­
cations in the United States. In the prevaccine era, varicella 
was a childhood disease with >90% of the 4 million cases, 
two thirds o f approximately 11,000 hospitalizations, and 
approximately half o f 100—150 annual deaths occurring among 
persons aged <20 years. Single-antigen varicella vaccine is 
licensed for use among healthy persons aged >12 months, and 
the combination M MRV vaccine is licensed for use in healthy 
children aged 12 m onths—12 years. Prelicensure and 
postlicensure studies have demonstrated that 1 dose o f single­
antigen varicella vaccine is approximately 85% effective in 
preventing varicella. Breakthrough varicella disease that 
occurs after vaccination frequently is mild and modified. 
Varicella vaccine is >95% effective in preventing severe vari­
cella disease. Since implementation of the varicella vaccina­
tion program in 1995, varicella incidence, hospitalizations, 
and deaths have declined substantially. M MRV was licensed 
on the basis o f immunological noninferiority to its vaccine 
antigenic components. Initial varicella vaccine policy recom­
mendations were for 1 dose o f varicella vaccine for children 
aged 12 months—12 years and 2 doses, 4—8 weeks apart, for 
persons aged >13 years. In June 2006, ACIP approved a rou­
tine 2-dose recommendation for children. The first dose should 
be administered at age 12—15 months and the second dose at 
age 4—6 years.
The rationale for the second dose o f varicella vaccine for 
children is to further decrease varicella disease and its compli­
cations in the United States. Despite the successes o f the 
1-dose vaccination program in children, vaccine effectiveness 
o f 85% has not been sufficient to prevent varicella outbreaks, 
which, although less than in the prevaccine era, have contin­
ued to occur in highly vaccinated school populations. Break­
through varicella is contagious. Studies o f the immune re­
sponse after 1 and 2 doses o f varicella vaccine demonstrate a 
greater-than-tenfold boost in GMTs when measured 6 weeks 
after the second varicella vaccine dose. A higher proportion 
(>99%) o f children achieve an antibody response o f >5 
gpELISA units after the second dose compared with 76% - 
85% of children after a single dose o f varicella vaccine. The 
second dose o f varicella vaccine is expected to provide im­
proved protection to the 15% -20%  o f children who do not 
respond adequately to the first dose. Data from a randomized 
clinical trial conducted postlicensure indicated that vaccine 
efficacy after 2 doses o f single-antigen varicella vaccine in chil­
dren (98.3%; CI = 97.3% -99.0% ) was significantly higher 
than that after a single dose (94.4%; CI =92.9% -95.7% ). 
The risk for breakthrough disease was 3.3-fold lower among 
children who received 2 doses than it was among children 
who received 1 dose. How this increase in vaccine efficacy 
(typically higher than observed under field conditions) will 
translate into vaccine effectiveness under conditions o f com­
munity use will be an important area o f study.
The recommended ages for routine first (at age 12-15 
months) and second (at age 4-6  years) doses o f varicella vac­
cine are harmonized with the recommendations for M M R 
vaccine use and intended to limit the period when children 
have no varicella antibody. The recommended age for the 
second dose is supported by the current epidemiology of 
varicella, with low incidence and few outbreaks among pre­
school-aged children and higher incidence and more outbreaks 
among elementary-school-aged children. However, the sec­
ond dose may be administered at an earlier age, provided that 
the interval between the first and second doses is 3 months. 
The recommendation for the minimum interval between doses 
is made on the basis o f the design o f the studies evaluating
2 doses among children aged 12 months-12 years. MMRV 
vaccine may be used to vaccinate children against measles, 
mumps, rubella, and varicella simultaneously. Because the risk 
for transmission can be high among students in schools, col­
leges, and other postsecondary educational institutions, stu­
dents without evidence o f immunity should receive 2 doses o f 
varicella vaccine. All children and adolescents who received
1 dose o f varicella vaccine previously should receive a second 
dose.
Varicella disease is more severe and its complications more 
frequent among adolescents and adults. The recommenda­
tion for vaccination of all adolescents and adults without 
evidence o f immunity will provide protection in these age 
groups. Because varicella m ight be more severe in 
immunocompromised persons who might not be eligible for
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vaccination, and because o f the risk o f VZV transmission in 
health-care settings, H CP must be vaccinated. Varicella dis­
ease during the first two trimesters o f pregnancy might infect 
the fetus and result in congenital varicella syndrome. There­
fore, routine antenatal screening for evidence o f immunity 
and postpartum vaccination for those without evidence of 
immunity now is recommended.
Recommendations for the Use 
of Varicella Vaccines
Two 0.5-mL doses o f varicella vaccine administered subcu­
taneously are recommended for children aged >12 months, 
adolescents, and adults without evidence o f immunity. For 
children aged 12 months-12 years, the recommended mini­
mum interval between the two doses is 3 months. However, if 
the second dose was administered >28 days after the first dose, 
the second dose is considered valid and need not be repeated. 
For persons aged >13 years, the recommended minimum 
interval is 4 weeks. Single-antigen varicella vaccine is approved 
for use among healthy persons aged >12 months. Combina­
tion MMRV vaccine is approved for use among healthy chil­
dren aged 12 months-12 years. M MRV vaccine is indicated 
for simultaneous vaccination against measles, mumps, rubella, 
and varicella. Whenever any components o f the combination 
vaccine are indicated and the other components are not 
contraindicated, use o f licensed combination vaccines, such 
as M M RV vaccine, is preferred over separate injection of 
equivalent component vaccines (157).
Routine Vaccination 
Persons Aged 12 Months-12 Years
Preschool-Aged Children
All healthy children should receive their first dose o f vari­
cella-containing vaccine routinely at age 12-15 months.
School-Aged Children
A second dose o f varicella vaccine is recommended routinely 
for all children aged 4 -6  years (i.e., before entering 
prekindergarten, kindergarten, or first grade). However, it may 
be administered at an earlier age provided that the interval 
between the first and second dose is >3 months.
Because o f the risk for transmission o f VZV in schools, all 
children entering school should have received 2 doses o f vari­
cella-containing vaccine or have other evidence o f immunity 
to varicella (see Evidence o f Immunity).
Persons Aged > 1 3  Years
Persons aged >13 years without evidence o f varicella immu­
nity should receive two 0.5-mL doses o f single-antigen vari­
cella vaccine administered subcutaneously, 4-8  weeks apart. 
If >8 weeks elapse after the first dose, the second dose may be 
administered without restarting the schedule. Only single­
antigen varicella vaccine may be used for vaccination o f per­
sons in this age group. M MRV is not licensed for use among 
persons aged >13 years.
School-Aged Children, College Students, and Students 
in Other Postsecondary Educational Institutions
All students should be assessed for varicella immunity, and 
those without evidence o f immunity should routinely receive
2 doses o f single-antigen varicella vaccine 4-8  weeks apart. 
The risk for transmission of varicella among school-aged chil­
dren, college students, and students in other postsecondary 
educational institutions can be high because o f high contact 
rates.
Other Adults
All healthy adults should be assessed for varicella immu­
nity, and those who do not have evidence o f immunity should 
receive 2 doses o f single-antigen varicella vaccine 4-8 weeks 
apart. Adults who might be at increased risk for exposure or 
transmission and who do not have evidence o f immunity 
should receive special consideration  for vaccination, 
including 1) HCP, 2) household contacts o f im m uno­
compromised persons, 3) persons who live or work in envi­
ronments in which transmission ofVZV is likely (e.g., teachers, 
day-care employees, residents and staff in institutional set­
tings), 4) persons who live or work in environments in which 
transmission has been reported (e.g., college students, inmates 
and staff members o f correctional institutions, and military 
personnel), 5) nonpregnant women of childbearing age, 6) 
adolescents and adults living in households with children, and 
7) international travelers.
Second Dose Catch-Up Vaccination
To improve individual protection against varicella and to 
have a more rapid impact on school outbreaks, second dose 
catch-up varicella vaccination is recommended for children, 
adolescents, and adults who previously received 1 dose. The 
recommended minimum interval between the first dose and 
the catch-up second dose is 3 months for children aged <12 
years and 4 weeks for persons aged >13 years. However, the 
catch-up second dose may be administered at any interval 
longer than the minimum recommended interval. Catch-up
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vaccination may be implemented during routine health-care 
provider visits and through school- and college-entry require­
ments.
As part o f comprehensive health services for all adolescents, 
ACIP, AAP, and AAFP recommend a health maintenance visit 
at age 11-12 years. This visit also should serve as an immuni­
zation visit to evaluate vaccination status and administer nec­
essary vaccinations (158). Physicians should use this and other 
routine visits to ensure that all children without evidence of 
varicella immunity have received 2 doses o f varicella vaccine.
Requirements for Entry to Child Care, 
School, College, and Other 
Postsecondary Educational Institutions
Child care and school entry requirements for varicella 
immunity have been recommended previously (2). In 2005, 
ACIP recommended expanding the requirements to cover stu­
dents in all grade levels. Official health agencies should take 
necessary steps, including developing and enforcing school 
immunization requirements, to ensure that students at all grade 
levels (including college) and children in child care centers 
are protected against varicella and other vaccine-preventable 
diseases (157).
Prenatal Assessment and Postpartum 
Vaccination
Prenatal assessment o f women for evidence o f varicella 
immunity is recommended. Birth before 1980 is not consid­
ered evidence o f immunity for pregnant women because of 
potential severe consequences ofvaricella infection during preg­
nancy, including infection of the fetus. Upon completion or 
termination o f their pregnancies, women who do not have 
evidence o f varicella immunity should receive the first dose of 
vaccine before discharge from the health-care facility. The sec­
ond dose should be administered 4-8  weeks later, which 
coincides with the postpartum visit (6-8 weeks after deliv­
ery). For women who gave birth, the second dose should be 
administered at the postpartum visit. Women should be coun­
seled to avoid conception for 1 month after each dose o f vari­
cella vaccine. Health-care settings in which completion or 
termination o f pregnancy occurs should use standing orders to 
ensure the administration o f varicella vaccine to women 
without evidence o f immunity.
Special Considerations 
for Vaccination 
Vaccination of HIV-Infected Persons
HIV-infected children with CD 4+ T-lymphocyte percent­
age >15% should be considered for vaccination with the single­
antigen varicella vaccine. Varicella vaccine was recommended 
previously for HIV-infected children in C D C  clinical and 
immunologic categories N1 and A1 with age-specific CD4+ 
T-lymphocyte percentage >25% (2). Limited data from a clini­
cal trial in which 2 doses o f single-antigen varicella vaccine 
were administered 3 months apart to 37 HIV-infected chil­
dren (C D C  clinical categories N , A, or B and immunologic 
category 2 [CD4+ T-lymphocyte percentage >15% —24%]) 
aged 1—8 years indicated that the vaccine was well-tolerated 
and that >80% o f subjects had detectable V Z V  specific 
immune response (either antibody or cell immune response 
or both) at 1 year after immunization (159). These children 
were no less likely to have an antibody response to the vari­
cella vaccine than were subjects who were less affected immu­
nologically by HIV infection. Because children infected with 
HIV are at increased risk for morbidity from varicella and 
H Z (i.e., shingles) compared with healthy children, ACIP rec­
ommends that, after weighing potential risks and benefits, 
single-antigen varicella vaccine should be considered for HIV- 
infected children with CD4+ T-lymphocyte percentages >15%. 
Eligible children should receive 2 doses o f single-antigen vari­
cella vaccine 3 months apart. Because persons with impaired 
cellular immunity are potentially at greater risk for complica­
tions after vaccination with a live vaccine, these vaccine 
recipients should be encouraged to return for evaluation if 
they experience a postvaccination varicella-like rash. Data are 
not available regarding safety, immunogenicity, or efficacy of 
M MRV vaccine in HIV-infected children, M MRV vaccine 
should not be administered as a substitute for the single­
antigen varicella vaccine when vaccinating these children. The 
titer o f Oka/Merck VZV is higher in combination MMRV 
vaccine than in single-antigen varicella vaccine. Recommen­
dations for vaccination o f HIV-infected children with measles, 
mumps, or rubella vaccines have been published previously 
(160).
Data on use o f varicella vaccine in HIV-infected adoles­
cents and adults are lacking. However, on the basis o f expert 
opinion, the safety o f varicella vaccine in HIV-infected per­
sons aged >8 years with comparable levels o f immune func­
tion (CD4+T-lymphocyte count >200 cells/^L) is likely to be
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similar to that o f children aged <8 years. Immunogenicity 
might be lower in older HIV-infected children, adolescents, 
and adults compared to children aged 1-8 years. However, 
weighing the risk for severe disease from wild VZV  and 
potential benefit o f vaccination, vaccination may be consid­
ered (2 doses, administered 3 months apart) for HIV-infected 
persons with CD4+T-lymphocytes count >200 cells/^L in 
these age groups. I f  vaccination o f HIV-infected persons 
results in clinical disease, the use o f acyclovir might modify 
the severity o f disease.
Situations in Which Some Degree 
of Immunodeficiency Might be Present
Persons with impaired humoral immunity may be vacci­
nated. No data have been published concerning whether per­
sons without evidence o f immunity receiving only inhaled, 
nasal, or topical doses o f steroids can be vaccinated safely. 
However, clinical experience suggests that vaccination is well- 
tolerated among these persons. Persons without evidence of 
immunity who are receiving systemic steroids for certain con­
ditions (e .g ., asthm a) and who are not otherwise 
immunocompromised may be vaccinated if they are receiving 
<2 mg/kg of body weight or a total o f <20 mg/day o f pred­
nisone or its equivalent. Certain experts suggest withholding 
steroids for 2-3 weeks after vaccination if it can be done safely 
(1). Data from a Japanese study using the Oka/Biken varicella 
vaccine (which is not available in the United States but whose 
immunogenicity and efficacy are similar to those o f the vari­
cella vaccine used in the United States) indicated that chil­
dren taking steroids for nephrosis were vaccinated safely when 
the steroids were suspended for 1-2 weeks before vaccina­
tion, although no serious reactions occurred among children 
vaccinated when steroid therapy was not suspended (161). 
Persons who are receiving high doses o f systemic steroids (i.e., 
>2 mg/kg prednisone) for >2 weeks may be vaccinated once 
steroid therapy has been discontinued for >1 month, in 
accordance with the general recommendations for the use o f 
live-virus vaccines (157).
Vaccination o f leukemic children who are in remission and 
who do not have evidence o f immunity to varicella should be 
undertaken only with expert guidance and with the availabil­
ity o f antiviral therapy should complications ensue. Patients 
with leukemia, lymphoma, or other malignancies whose dis­
ease is in remission and whose chemotherapy has been termi­
nated for at least 3 months can receive live-virus vaccines (157). 
When immunizing persons in whom some degree o f immu­
nodeficiency might be present, only single-antigen varicella 
vaccine should be used.
Vaccination of Household Contacts 
of Immunocompromised Persons
Immunocompromised persons are at high risk for serious 
varicella infections. Severe disease occurs in approximately 30% 
of such persons with primary infection. Because varicella vac­
cine now is recommended for all healthy children and adults 
without evidence o f  immunity, household contacts o f 
immunocompromised persons should be vaccinated routinely. 
A lthough the risk for exposure to wild V Z V  for 
immunocompromised persons now is lower than it was pre­
viously, vaccine should be offered to child and adult house­
hold contacts w ithout evidence o f  im m unity o f  
immunocompromised persons. Vaccination o f household con­
tacts provides protection for immunocompromised persons 
by decreasing the likelihood that wild-type VZV will be 
introduced into the household. Vaccination o f household con­
tacts o f immunocompromised persons theoretically might pose 
a m inim al risk for transm ission  o f  vaccine virus to 
immunocompromised persons, although in one study, no evi­
dence o f transmission o f vaccine virus was demonstrated after 
vaccination of 37 healthy siblings o f 30 children with malig­
nancy (155). No cases have been documented o f transmission 
o f vaccine virus to immunocompromised persons in the 
postlicensure period in the United States, with >55 million 
doses o f vaccine distributed. Other data indicate that disease 
caused by vaccine virus in immunocompromised persons is 
milder than wild-type disease and can be treated with acyclovir 
(148,159). The benefits o f vaccinating susceptible household 
contacts o f immunocompromised persons outweigh the 
extremely low potential risk for transmission o f vaccine virus 
to immunocompromised contacts. Vaccine recipients in whom 
vaccine-related rash occurs, particularly HCP and household 
contacts o f immunocompromised persons, should avoid con­
tact with susceptible persons who are at high risk for severe 
complications. If a susceptible, immunocompromised person 
is inadvertently exposed to a person who has a vaccine-related 
rash, postexposure prophylaxis with V ZIG  is not needed 
because disease associated with this type o f virus is expected 
to be mild.
Nursing Mothers
Postpartum vaccination o f women without evidence o f im­
munity need not be delayed because o f breastfeeding. Women 
who have received varicella vaccination postpartum may con­
tinue to breastfeed. The majority o f live vaccines are not asso­
ciated with virus secretion in breast milk (157). A study 
involving 12 women who received single-antigen varicella vac­
cine while breastfeeding indicated no evidence ofV Z V  DNA
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either in 217 breast milk samples collected or in infants tested 
after both vaccine doses (162). No infants seroconverted. 
Another study did not detect varicella gene sequences in the 
postvaccination breast milk samples (163). Therefore, single­
antigen varicella vaccine should be administered to nursing 
mothers without evidence o f immunity. Combination MMRV 
vaccine is not licensed for use among persons aged >13 years.
Health-Care Personnel
Nosocom ial transm ission o f VZV is well-recognized 
(131,164—173), and guidelines for the prevention o f nosoco­
mial VZV infection and for infection control in H CP have 
been published (174,175). Sources o f nosocomial exposure 
have included patients, hospital staff, and visitors (e.g., the 
children o f hospital employees) who are infected with vari­
cella or HZ. In hospitals, airborne transmission of VZV has 
been demonstrated when varicella has occurred in susceptible 
persons who had no direct contact with the index case- 
patient (176—180).
To prevent disease and nosocomial spread of VZV, health­
care institutions should ensure that all HCP have evidence of 
immunity to varicella. Birth before 1980 is not considered 
evidence o f immunity for HCP because o f the possibility of 
nosocomial transmission to high-risk patients. In health-care 
institutions, serologic screening before vaccination o f person­
nel who have a negative or uncertain history o f varicella and 
who are unvaccinated is likely to be cost effective. Institutions 
may elect to test all HCP regardless o f disease history because 
a small proportion o f persons with a positive history of 
disease might be susceptible.
Routine testing for varicella immunity after 2 doses o f vac­
cine is not recommended for the management o f vaccinated 
HCP. Available commercial assays are not sensitive enough to 
detect antibody after vaccination in all instances. Sensitive tests 
have indicated that 99% of adults develop antibodies after 
the second dose. However, seroconversion does not always 
result in full protection against disease, and no data regarding 
correlates o f protection are available for adults.
H CP who have received 2 doses o f vaccine and who are 
exposed to VZV should be monitored daily during days 10­
21 after exposure through the employee health program or by 
an infection control nurse to determine clinical status (i.e., 
daily screen for fever, skin lesions, and systemic symptoms). 
Persons with varicella might be infectious up to 2 days before 
rash onset. In addition, HCP should be instructed to report 
fever, headache, or other constitutional symptoms and any 
atypical skin lesions immediately. H CP should be placed on 
sick leave immediately if symptoms occur. Health-care insti­
tutions should establish protocols and recommendations for
screening and vaccinating H CP and for management o f HCP 
after exposures in the work place.
HCP who have received 1 dose o f vaccine and who are 
exposed to VZV should receive the second dose with single­
antigen varicella vaccine within 3—5 days after exposure to 
rash (provided 4 weeks have elapsed after the first dose). After 
vaccination, management is similar to that o f 2-dose vaccine 
recipients.
Unvaccinated HCP who have no other evidence o f immu­
nity who are exposed to VZV are potentially infective from 
days 10—21 after exposure and should be furloughed during 
this period. They should receive postexposure vaccination as 
soon as possible. Vaccination within 3—5 days o f exposure to 
rash might modify the disease if infection occurred. Vaccina­
tion >5 days postexposure still is indicated because it induces 
protection against subsequent exposures (if the current 
exposure did not cause infection).
The risk for transmission o f vaccine virus from vaccine 
recipients in whom varicella-like rash occurs after vaccination 
is low and has been documented after exposures in house­
holds and long-term care facilities (140,146—148). No cases 
have been documented after vaccination of HCP. The ben­
efits o f vaccinating HCP without evidence o f immunity out­
weigh this extremely low potential risk. As a safeguard, 
institutions should consider precautions for personnel in whom 
rash occurs after vaccination. H CP in whom a vaccine-related 
rash occurs should avoid contact with persons without 
evidence o f immunity who are at risk for severe disease and 
complications until all lesions resolve (i.e., are crusted over or 
fade away) or no new lesions appear within a 24-hour period.
Varicella IgG Antibody Testing
The tests most widely used to detect varicella IgG antibody 
after natural varicella infection among H CP are latex aggluti­
nation (LA) and ELISA. A commercially available LA test using 
latex particles coated with VZV glycoprotein antigens can be 
completed in 15 minutes and does not require special equip­
ment (181). The sensitivity and specificity o f the LA test are 
comparable to those o f FAMA in detecting antibody response 
after natural varicella infection. The LA test generally is more 
sensitive than commercial ELISAs. The LA test has detected 
antibody for up to 11 years after varicella vaccination (182). 
However, for the purpose o f screening HCP for varicella sus­
ceptibility, a less sensitive and more specific commercial ELISA 
should be considered. A recent report indicated that the LA 
test can produce false-positive results, particularly when only 
a single concentration o f serum is evaluated (183); this led to 
documented cases o f false-positive results in HCP who conse­
quently remained unvaccinated and subsequently contracted 
varicella.
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Vaccination for Outbreak Control
Varicella vaccination is recommended for outbreak control. 
Persons who do not have adequate evidence ofimmunity should 
receive their first or second dose as appropriate. Additionally, in 
outbreaks among preschool-aged children, 2-dose vaccination 
is recommended for optimal protection, and children vacci­
nated with 1 dose should receive their second dose provided
3 months have elapsed since the first dose. State and local health 
departments may advise exposed persons who do not have evi­
dence o f immunity to contact their health-care providers for 
vaccination, or they may offer vaccination through the health 
department or school (or other institutions) vaccination clin­
ics. Although outbreak control efforts optimally should be imple­
mented as soon as an outbreak is identified, vaccination should 
be offered even if the outbreak is identified late. Varicella out­
breaks in certain settings (e.g., child care facilities, schools, or 
institutions) can last as long as 4-5 months. Thus, offering vac­
cine during an outbreak might provide protection to persons 
not yet exposed and shorten the duration of the outbreak (184). 
Persons receiving either their first or second dose as part o f the 
outbreak control program may be readmitted to school imme­
diately. Those vaccinated with the first dose as part o f outbreak 
control measures should be scheduled for the second dose as 
age appropriate. Persons who are unvaccinated and without other 
evidence o f immunity who do not receive vaccine should be 
excluded from institutions in which the outbreak is occurring 
until 21 days after the onset o f rash in the last case o f varicella. 
In addition, for school-aged persons covered by the 2-dose school 
vaccination requirements, exclusion during an outbreak is rec­
ommended for those vaccine recipients who had received the 
first dose before the outbreak but not the second as part o f the 
oubtreak control program. Persons at increased risk for severe 
varicella who have contraindications to vaccination should 
receive VZIG within 96 hours o f exposure.
Contraindications 
General
Adequate treatment provisions for anaphylactic reactions, 
including epinephrine injection (1:1000), should be available 
for immediate use should an anaphylactic reaction occur. 
Before administering a vaccine, health-care providers should 
obtain the vaccine recipient’s vaccination history and deter­
mine whether the individual had any previous reactions to 
any vaccine including VARIVAX, ProQuad or any measles, 
mumps, or rubella containing vaccines.
Allergy to Vaccine Components
The administration o f live varicella-containing vaccines 
rarely results in hypersensitivity. The information in the pack­
age insert should be reviewed carefully before vaccine is 
administered. Vaccination is contraindicated for persons who 
have a history o f anaphylactic reaction to any component o f 
the vaccine, including gelatin. Single-antigen varicella vaccine 
does not contain preservatives or egg protein; these substances 
have caused hypersensitive reactions to other vaccines. For the 
combination M MRV vaccine, live measles and live mumps 
vaccines are produced in chick embryo culture. However, 
among persons who are allergic to eggs, the risk for serious 
allergic reactions after administration of measles- or mumps- 
containing vaccines is low. Because skin testing with vaccine 
is not predictive o f allergic reaction to vaccination, skin test­
ing is not required before administering combination MMRV 
vaccine to persons who are allergic to eggs (160). The major­
ity o f anaphylactic reactions to measles- and mumps- 
containing vaccines are associated not with hypersensitivity 
to egg antigens but with other vaccine components. Neither 
single-antigen varicella nor combination M MRV vaccines 
should be administered to persons who have a history o f ana­
phylactic reaction to neomycin. However, neomycin allergy 
usually is manifested as a contact dermatitis, which is a delayed- 
type immune response rather than anaphylaxis. For persons 
who experience such a response, the adverse reaction, if any, 
would appear as an erythematous, pruritic nodule or papule 
present 48-96 hours after vaccination. A history o f contact 
dermatitis to neomycin is not a contraindication to receiving 
varicella vaccines.
Altered Immunity
Single-antigen varicella and combination MMRV vaccines 
are not licensed for use in persons who have any malignant 
condition, including blood dyscrasias, leukemia, lymphomas 
of any type, or other malignant neoplasms affecting the bone 
marrow or lymphatic systems. Combination MMRV vaccine 
should not be administered to persons with primary or acquired 
immunodeficiency, including immunosuppression associated 
with AIDS or other clinical manifestations o f HIV infections, 
cellular immunodeficiencies, hypogammaglobulinemia, and 
dysgammaglobulinemia. Combination MMRV vaccine should 
not be administered as a substitute for the component vaccines 
when vaccinating HIV-infected children.
Varicella vaccines should not be administered to persons 
who have a family history o f congenital or hereditary immu­
nodeficiency in first-degree relatives (e.g., parents and siblings) 
unless the immune competence o f the potential vaccine
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recipient has been clinically substantiated or verified by a 
laboratory.
Varicella vaccines should not be administered to persons 
receiving high-dose systemic immunosuppressive therapy, 
including persons on oral steroids >2 mg/kg o f body weight 
or a total o f >20 mg/day o f prednisone or equivalent for per­
sons who weigh >10 kg, when administered for >2 weeks. 
Such persons are more susceptible to infections than healthy 
persons. Administration o f varicella vaccines can result in a 
more extensive vaccine-associated rash or disseminated dis­
ease in persons receiving immunosuppressive doses o f corti­
costeroids (185). This contraindication does not apply to 
persons who are receiving inhaled, nasal, or topical corticos­
teroids or low-dose corticosteroids as are used commonly for 
asthma prophylaxis or for corticosteroid-replacement therapy 
(see Situations in Which Some Degree o f Immunodeficiency 
Might Be Present).
Pregnancy
Because the effects o f the varicella virus vaccine on the fetus 
are unknown, pregnant women should not be vaccinated. 
Nonpregnant women who are vaccinated should avoid 
becoming pregnant for 1 month after each injection. For per­
sons without evidence o f immunity, having a pregnant house­
hold member is not a contraindication to vaccination.
If a pregnant woman is vaccinated or becomes pregnant 
within 1 month of vaccination, she should be counseled about 
potential effects on the fetus. Wild-type varicella poses a low 
risk to the fetus (see Prenatal and Perinatal Exposure). 
Because the virulence o f the attenuated virus used in the vac­
cine is less than that o f the wild-type virus, the risk to the 
fetus, if any, should be even lower. In 1995, Merck and Co., 
Inc., in collaboration with C D C , established the VARIVAX 
Pregnancy Registry to monitor the maternal-fetal outcomes 
o f pregnant women who were inadvertently administered 
varicella vaccine 3 months before or at any time during preg­
nancy (to report, call: 1-800-986-8999) (186). During the 
first 10 years o f the pregnancy registry no cases o f congenital 
varicella syndrome or birth defects compatible with congeni­
tal varicella syndrome have been documented (187,188). 
Among 131 live-born infants o f prospectively reported serone­
gative women (82 o f whom were born to mothers vaccinated 
during the highest risk period [i.e., the first or second trimes­
ter o f pregnancy]), no birth defects consistent with congeni­
tal varicella syndrome have been documented (prevalence 
rate = 0; CI = 0—6.7%), and three major birth defects were 
reported (prevalence rate = 2.3%; CI = 0.5%—6.7%). The rate 
o f occurrence o f major birth defects from prospective reports
in the registry was similar to the rate reported in the general 
U.S. population (3.2%), and the defects indicated no specific 
pattern or target organ. Although the study results do not 
exclude the possibility o f risk for women who received inad­
vertent varicella vaccination before or during pregnancy, the 
potential risk, if any, is low.
Precautions
Illness
Vaccination o f persons who have acute severe illness, 
including untreated, active tuberculosis, should be postponed 
until recovery. The decision to delay vaccination depends on 
the severity o f symptoms and on the etiology of the disease. 
No data are available regarding whether either single-antigen 
varicella or combination MMRV vaccines exacerbate tuber­
culosis. Live attenuated measles, mumps, and rubella virus 
vaccines administered individually might result in a tempo­
rary depression o f tuberculin skin sensitivity. Therefore, if a 
tuberculin test is to be performed, it should be administered 
either any time before, simultaneously with, or at least 4-6  
weeks after combination M MRV vaccine. However, tubercu­
lin skin testing is not a prerequisite for vaccination with single­
antigen varicella or combination MMRV vaccines.
Varicella vaccines may be administered to children without 
evidence o f immunity who have mild illnesses, with or with­
out low-grade fever (e.g., diarrhea or upper-respiratory infec­
tion) (189). Physicians should be alert to the vaccine-associated 
temperature elevations that might occur predominantly in the 
second week after vaccination, especially with combination 
MMRV vaccine. Studies suggest that failure to vaccinate chil­
dren with minor illnesses can impede vaccination efforts (190).
Thrombocytopenia
Thrombocytopenia is not a contraindication for single­
antigen varicella vaccine. No clinical data are available regard­
ing the development or worsening o f thrombocytopenia in 
persons vaccinated with combination M MRV vaccine. Cases 
o f thrombocytopenia have been reported after M M R vaccine 
and after varicella vaccination. Postmarketing experience with 
live M M R vaccine indicates that persons with thrombocy­
topenia might develop more severe thrombocytopenia after 
vaccination. For vaccination o f thrombocytopenic children 
with combination M M RV vaccine, health-care providers 
should refer to the ACIP recommendations on M M R vacci­
nation (160).
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Recent Administration of Blood, 
Plasma, or Immune Globulin
Although passively acquired antibody is known to interfere 
with response to measles and rubella vaccines (191), the effect 
o f the administration o f immune globulin (IG) on the 
response to varicella virus vaccine is unknown. The duration 
of interference with the response to measles vaccination is dose- 
related and ranges from 3-11 months. Because o f the poten­
tial inhibition o f the response to varicella vaccination by 
passively transferred antibodies, varicella vaccines should not 
be administered for the same intervals as measles vaccine 
(3 -1 1  m onths, depending on the dosage) after 
administration o f blood (except washed red blood cells), 
plasma, or IG. Suggested intervals between administration of 
antibody-containing products for different indications and 
varicella vaccine have been published previously (157). In 
addition, persons who received a varicella vaccine should not 
be administered an antibody-containing product for 2 weeks 
after vaccination unless the benefits exceed those o f vaccina­
tion. In such cases, the vaccine recipient should either be 
revaccinated or tested for immunity at the appropriate inter­
vals, depending on the dose received, and then revaccinated if 
seronegative.
Use of Salicylates
No adverse events associated with the use o f salicylates after 
varicella vaccination have been reported; however, the vaccine 
manufacturer recommends that vaccine recipients avoid 
using salicylates for 6 weeks after receiving varicella vaccines 
because o f the association between aspirin use and Reye syn­
drome after varicella. Vaccination with subsequent close moni­
toring should be considered for children who have rheumatoid 
arthritis or other conditions requiring therapeutic aspirin. The 
risk for serious complications associated with aspirin is likely 
to be greater in children in whom natural varicella develops 
than it is in children who receive the vaccine containing 
attenuated VZV. No association has been documented 
between Reye syndrome and analgesics or antipyretics that do 
not contain salicylic acid.
Postexposure Prophylaxis 
Healthy Persons
Prelicensure data from the United States and Japan on vari­
cella exposures in children from household, hospital, and com­
munity settings indicate that single-antigen varicella vaccine
is effective in preventing illness or modifying varicella severity 
if administered to unvaccinated children within 3 days, and 
possibly up to 5 days, o f exposure to rash (78,101,192). Vac­
cination within 3 days o f exposure to rash was >90% effective 
in preventing varicella whereas vaccination within 5 days o f 
exposure to rash was approximately 70% effective in prevent­
ing varicella and 100% effective in modifying severe disease 
(101,192). Limited postlicensure studies also have demon­
strated that varicella vaccine is highly effective in either pre­
venting or modifying disease if administered within 3 days o f 
exposure (193,194). Varicella vaccine is recommended for 
postexposure administration for unvaccinated persons with­
out other evidence o f immunity. I f  exposure to VZV does not 
cause infection, postexposure vaccination should induce pro­
tection against subsequent exposures. I f  the exposure results 
in infection, no evidence indicates that administration of 
single-antigen varicella vaccine during the presymptomatic or 
prodromal stage o f illness increases the risk for vaccine- 
associated adverse events. No data are available regarding the 
potential benefit o f administering a second dose to 1-dose 
vaccine recipients after exposure. However, administration of 
a second dose should be considered for persons who have pre­
viously received 1 dose to bring them up-to-date. Studies on 
postexposure use o f varicella vaccine have been conducted 
exclusively in children. A higher proportion o f adults do not 
respond to the first dose o f varicella vaccine. Nevertheless, 
postexposure vaccination should be offered to adults without 
evidence o f immunity. Although postexposure use o f varicella 
vaccine has potential applications in hospital settings, vacci­
nation is recommended routinely for all HCP without evi­
dence o f immunity and is the preferred method for preventing 
varicella in health-care settings (195). Preferably, HCP should 
be vaccinated when they begin employment. No data are avail­
able on the use o f  com bination  M M R V  raccine for 
postexposure prophylaxis.
Persons Without Evidence of Immunity 
Who Have Contraindications 
for Vaccination and Who Are at Risk 
for Severe Disease and Complications
Studies conducted in 1969 indicated that clinical varicella 
was prevented in nonimmune, healthy children by the 
administration o f zoster immune globulin (ZIG) (prepared 
from patients recovering from HZ) within 72 hours o f expo­
sure (196 ). Z IG  also lowered attack rates am ong 
immunocompromised persons if administered no later than 
96 hours after exposure (196). VZIG (prepared from plasma
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obtained from healthy, volunteer blood donors identified by 
routine screening to have high antibody titers to VZV) 
became available in 1978. Both serologic and clinical evalua­
tions have demonstrated that the product is equivalent to ZIG 
in preventing or modifying clinical illness in non-immune, 
immunocompromised persons who are exposed to varicella 
(197,198). In a study o f immunocompromised children who 
were administered V Z IG  within 96 hours o f exposure, 
approximately one in five exposures resulted in clinical vari­
cella, and one in 20 resulted in subclinical disease (198). The 
severity o f clinical varicella (evaluated by percentage of 
patients with >100 lesions or complications) was lower than 
expected on the basis o f historic controls.
The VZIG product currently used in the United States, 
VariZIG™(Cangene Corporation, Winnipeg, Canada), is 
available under an Investigational New Drug Application 
Expanded Access protocol (available at http://www.fda.gov/ 
cber/infosheets/mphvzig020806.htm). A request for licensure 
in the United States might be submitted to FDA in the future. 
VariZIG is a lyophilized presentation which, when properly 
reconstituted, is approximately a 5% solution of IgG that can 
be administered intramuscularly (199). VariZIG can be 
obtained 24 hours a day from the sole authorized U.S. 
distributor (FFF Enterprises, Temecula, California) at 1-800­
843-7477 or online at http://www.fffenterprises.com.
Administration of VZIG
VZIG provides maximum benefit when administered as 
soon as possible after exposure, but it might be effective if 
administered as late as 96 hours after exposure. The effective­
ness o f V ZIG  when administered >96 hours after initial 
exposure has not been evaluated. The duration of protection 
provided after administration ofV ZIG  is unknown, but pro­
tection should last at least one half-life o f the IG (i.e., 
approximately 3 weeks). Susceptible persons at high risk for 
whom varicella vaccination is contraindicated and who are 
again exposed >3 weeks after receiving a dose ofVZIG  should 
receive another full dose ofVZIG. Patients receiving monthly 
high-dose immune globulin intravenous (IGIV) (>400 mg/ 
kg) are likely to be protected and probably do not require 
VZIG if the last dose o f IGIV was administered <3 weeks 
before exposure (200). VZIG has not been proven to be use­
ful in treating clinical varicella or H Z or in preventing dis­
seminated zoster and is not recommended for such use. VZIG 
might extend the incubation period of the virus from 10—21 
days to >28 days. This should be taken into account after 
exposures when VZIG is administered.
Dosage
VariZIG is supplied in 125-U vials. The recommended dose 
is 125 units/10 kg o f body weight, up to a maximum o f 625 
units (five vials). The minimum dose is 125 U. The human 
IgG content is 60—200 mg per 125 units dose o f VariZIG.
Indications for the Use of VZIG 
for Postexposure Prophylaxis
The decision to administer VZIG depends on three factors:
1) whether the patient lacks evidence o f immunity, 2) whether 
the exposure is likely to result in infection, and 3) whether the 
patient is at greater risk for complications than the general 
population.
Both healthy and immunocompromised children and adults 
who have verified positive histories ofvaricella (except for bone- 
marrow transplant recipients) may be considered immune (see 
Evidence o f Immunity). The association between positive his­
tories o f varicella in bone-marrow donors and susceptibility 
to varicella in recipients after transplants has not been studied 
adequately. Thus, persons who receive bone-marrow trans­
plants should be considered nonimmune, regardless o f previ­
ous history o f varicella disease or varicella vaccination in 
themselves or in their donors. Bone-marrow recipients in 
whom varicella or H Z develops after transplantation should 
subsequently be considered immune.
VZIG is not indicated for persons who received 2 doses o f 
varicella vaccine and became immunocompromised as a 
result o f disease or treatment later in life. These persons should 
be monitored closely; if disease occurs, treatment with acyclovir 
should be instituted at the earliest signs or symptoms. For 
patients without evidence o f immunity and on steroid therapy 
doses >2 mg/kg of body weight or a total o f 20 mg/day of 
prednisone or equivalent, VariZIG is indicated.
Types of Exposure
Certain types o f exposure can place persons without evi­
dence o f immunity at risk for varicella. Direct contact expo­
sure is defined as face-to-face contact with an infectious person 
while indoors. The duration of face-to-face contact that war­
rants administration of VZIG is not certain. However, the 
contact should not be transient. Certain experts suggest a con­
tact o f >5 minutes as constituting significant exposure for this 
purpose, whereas others define close contact as >1 hour (200). 
Substantial exposure for hospital contacts consists o f sharing 
the same hospital room with an infectious patient or direct, 
face-to-face contact with an infectious person (e.g., HCP). 
Brief contacts with an infectious person (e.g., contact with
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x-ray technicians or housekeeping personnel) are less likely 
than more prolonged contacts to result in VZV transmission.
Persons with continuous exposure to household members 
who have varicella or disseminated H Z are at greatest risk for 
infection. Varicella occurs in approximately 85% (range: 65% - 
100%) o f susceptible household contacts exposed to VZV. 
Localized H Z is much less infectious than varicella or dis­
seminated H Z (52). Transmission from localized H Z is more 
likely after close contact, such as in household settings. Physi­
cians may consider recommending postexposure prophylaxis 
with VZIG in such circumstances. After household exposure 
to varicella, attack rates among immunocompromised chil­
dren who were administered VZIG were up to 60% (197). 
No comparative data are available for immunocompromised 
children without evidence o f immunity who were not admin­
istered V ZIG . However, the incidence o f severe disease 
(defined as >100 skin lesions) was less than that predicted 
from the natural history o f disease in normal children (27% 
and 87%, respectively), and the incidence o f pneumonia was 
less than that described in children with neoplasm (6% and 
25%, respectively) (201). The risk for varicella after close con­
tact (e.g., contact with playmates) or hospital exposure is esti­
mated to be approximately 20% o f the risk occurring from 
household exposure.
The attack rate in healthy neonates who were exposed in 
utero within 7 days o f delivery and who received VZIG after 
birth was 62%, which does not differ substantially from rates 
reported for neonates who were similarly exposed but not 
treated with VZIG (49). However, the occurrence o f compli­
cations and fatal outcomes was substantially lower for neo­
nates who were treated with VZIG than for those who were 
not.
In a study of pregnant women without immunity to VZV 
who were exposed to varicella and administered VZIG, the 
infection rate was 30%. This is substantially lower than the 
expected rate o f >70% in unimmunized women exposed to 
varicella (199,202).
Recommendations for the Use of VZIG
The following patient groups are at risk for severe disease 
and complications from varicella and should receive VZIG:
Immunocompromised patients. VZIG is used primarily 
for passive immunization of immunocompromised persons 
without evidence o f immunity after direct exposure to vari­
cella or disseminated H Z  patients, including persons who
1) have primary and acquired immune-deficiency disorders,
2) have neoplastic diseases, and 3) are receiving immunosup­
pressive treatment. Patients receiving monthly high-dose IGIV 
(>400 mg/kg) are likely to be protected and probably do not
require V ZIG  if the last dose o f IGIV was administered 
<3 weeks before exposure (200).
Neonates whose mothers have signs and symptoms of 
varicella around the time o f delivery. VZIG is indicated for 
neonates whose mothers have signs and symptoms of varicella 
from 5 days before to 2 days after delivery. VZIG is not neces­
sary for neonates whose mothers have signs and symptoms of 
varicella more than 5 days before delivery, because those 
infants should be protected from severe varicella by transpla­
centally acquired maternal antibody. No evidence suggests that 
infants born to mothers in whom varicella occurs >48 hours 
after delivery are at increased risk for serious complications 
(e.g., pneumonia or death).
Premature neonates exposed postnatally. Transmission of 
varicella in the hospital nursery is rare because the majority of 
neonates are protected by maternal antibody. Premature 
infants who have substantial postnatal exposure should be 
evaluated on an individual basis. The risk for complications 
o f postnatally acquired varicella in premature infants is 
unknown. However, because the immune system o f prema­
ture infants is not fully developed, administration of VZIG to 
premature infants born at >28 weeks o f gestation who are 
exposed during the neonatal period and whose mothers do 
not have evidence o f immunity is indicated. Premature 
infants born at <28 weeks o f gestation or who weigh <1,000 g 
at birth and were exposed during the neonatal period should 
receive VZIG regardless o f maternal immunity because such 
infants might not have acquired maternal antibody. The 
majority o f premature infants born at >28 weeks o f gestation 
to immune mothers have enough acquired maternal antibody 
to protect them from severe disease and complications. 
Although infants are at higher risk than older children for 
serious and fatal complications, the risk for healthy, full-term 
infants who have varicella after postnatal exposure is substan­
tially less than that for infants whose mothers were infected 
5 days before to 2 days after delivery. VZIG is not recom­
mended for healthy, full-term infants who are exposed post­
natally, even if their mothers have no history o f varicella 
infection.
Pregnant women. Because pregnant women might be at 
higher risk for severe varicella and complications (37,42,203), 
VZIG should be strongly considered for pregnant women 
without evidence o f immunity who have been exposed. 
Administration o f VZIG to these women has not been found 
to prevent viremia, fetal infection, congenital varicella syn­
drome, or neonatal varicella. Thus, the primary indication for 
V ZIG  in pregnant women is to prevent complications of 
varicella in the mother rather than to protect the fetus. 
Neonates born to mothers who have signs and symptoms of
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varicella from 5 days before to 2 days after delivery should 
receive VZIG , regardless o f whether the mother received 
VZIG.
Interval Between Administration 
of VZIG and Varicella Vaccine
Any patient who receives VZIG to prevent varicella should 
receive varicella vaccine subsequently, provided the vaccine is 
not contraindicated. Varicella vaccination should be delayed 
until 5 months after VZIG administration. Varicella vaccine 
is not needed if the patient has varicella after administration 
of VZIG.
Antiviral Therapy
Because VZIG might prolong the incubation period by 
>1 week, any patient who receives VZIG should be observed 
closely for signs or symptoms of varicella for 28 days after 
exposure. Antiviral therapy should be instituted immediately 
if signs or symptoms of varicella disease occur. The route and 
duration o f antiviral therapy should be determined by spe­
cific host factors, extent o f infection, and initial response to 
therapy. Information regarding how to obtain VariZIG is avail­
able at http://www.cdc.gov/mmwr/preview/mmwrhtml/ 
mm5508a5.htm (204).
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Appendix
Summary of Recommendations for Varicella Vaccination
Routine Childhood Schedule
•  Routine childhood vaccination should be 2 doses.
• Preschool-aged children should receive the first dose of 
varicella vaccine at age 12-15 months.
• School-aged children should receive the second dose at 
age 4 -6  years (may be administered earlier provided 
>3 months have elapsed after the first dose)
Persons Aged >13 Years
•  Persons aged >13 years should receive 2 doses o f vaccine, 
doses (4-8 weeks apart).
• All adolescents and adults without evidence o f immunity 
should be vaccinated.
• Because o f their increased risk for transmission to per­
sons at high risk for severe disease or their increased risk 
o f exposure, vaccination is especially important for per­
sons without evidence o f immunity in the following 
groups:
—  persons who have close contact with persons at high 
risk for serious complications (e.g., health-care per­
sonnel and household contacts o f immunocompro­
mised persons);
—  persons who live or work in environments in which 
transmission of varicella zoster virus is likely (e.g., 
teachers, child-care workers, and residents and staff in 
institutional settings);
—  persons who live and work in environments in which 
transmission has been reported (e.g., college students, 
inmates and staff members of correctional institutions, 
military personnel);
—  nonpregnant women o f childbearing age;
—  adolescents and adults living in households with 
children; and
—  international travelers.
Prenatal Assessment and Postpartum 
Vaccination
Prenatal assessment o f women for evidence o f varicella 
immunity is recommended. Upon completion or termination 
of pregnancy, women who do not have evidence of varicella 
immunity should be vaccinated.
Vaccination of HIV-Infected Persons
Vaccination should be considered for HIV-infected children 
with age-specific CD 4+ T-lymphocyte percentage >15% and 
may be considered for adolescents and adults in with CD4+ 
T-lymphocyte count >200 cells/^L.
Outbreak Control
• 2-dose vaccination policy
Postexposure Prophylaxis
• Recommended within 3-5 days
Requirements for Entry to Child Care, 
School, College, and Other 
Postsecondary Educational Institutions
All states should require that students at all grade levels 
(including college) and those in child care centers receive 
varicella vaccine unless they have other evidence of immunity 
of varicella.
Evidence of Immunity to Varicella
Evidence o f immunity to varicella includes any of the 
following:
• documentation of age-appropriate vaccination with a 
varicella vaccine:
—  preschool-aged children (i.e., aged >12 months): 1 dose
—  school-aged children, adolescents, and adults: 2 doses*
• laboratory evidence o f immunity^ or laboratory confir­
mation o f disease;
• birth in the United States before 1980§;
• diagnosis or verification of a history o f varicella disease 
by a health-care provider^; or
• diagnosis or verification o f a history o f herpes zoster by a 
health-care provider.
* For children w ho received their first dose a t age <13 years and for w hom  the interval between the 2 doses was >28 days, the  second dose is considered valid.
 ̂ Com m ercial assays can be used to assess disease-induced im m unity, b u t they lack sensitivity to always detect vaccine-induced im m unity  (i.e., they m ight yield
false-negative results).
§ For health-care personnel, pregnant w om en, and im m unocom prom ised persons, b irth  before 1980 should  n o t be considered evidence o f im m unity.
^ V erification o f  history or diagnosis o f  typical disease can be provided by any health-care provider (e.g., school or occupational clinic nurse, nurse practitioner, 
physician assistant, or physician). For persons reporting a history of, or reporting w ith, atypical or m ild cases, assessment by a physician or their designee is 
recom m ended, and one o f the  following should  be sought: 1) an epidem iologic link  to a typical varicella case or to a laboratory-confirm ed case or 2) evidence of 
laboratory confirm ation  if it was perform ed a t the  tim e of acute disease. W h en  such docum entation  is lacking, persons should  n o t be considered as having a valid 
history o f disease because o ther diseases m igh t m im ic m ild  atypical varicella.
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_________________________________________ Goal and Objectives_________________________________________
This report revises, updates, and replaces the 1996 and 1999 ACIP statements o f C D C ’s Advisory Committee on Immunization Practices for prevention o f varicella 
in the United States. The goal o f this report is to improve the health status o f the U.S. population by providing recommendations on the use of varicella vaccines for 
prevention ofvaricella disease. Upon completion o f this educational activity, the reader should be able to 1) describe the epidemiology ofvaricella in the United States, 
2) identify recommendations for varicella vaccination in the United States, and 3) describe the characteristics o f  the currently licensed varicella vaccines.
To receive continuing education credit, please answer all of the following questions.
1. Which o f the following are recommendations for the use o f varicella 7. 
vaccines? (Indicate a ll that apply.)
A. Children aged 12 months—12 years should routinely receive 2 doses of 
varicella vaccine at age 12—15 months and at age 4—6 years, 
respectively.
B. Children can receive the second dose earlier than age 4—6 years, 
provided >3 months have elapsed after the first dose.
C. Persons aged >13 years and without evidence of immunity should 
receive 2 doses o f vaccine 4—8 weeks apart.
D. A catch-up second dose is recommended for children, adolescents, and 
adults who had received 1 dose.
E. All o f the above.
2. Among persons aged >13 years without evidence o f immunity, which 
groups should receive special consideration for vaccination? (Indicate 
all that apply.)
A. Students in postsecondary educational institutions.
B. Health-care providers.
C. Household contacts of immunocompromised persons.
D. Persons at high risk for exposure or transmission.
E. W om en o f child bearing age.
F. International travelers.
G. All o f the above.
3. Which of the following is not a criterion for evidence of immunity to 
varicella?
A. Documentation of age-appropriate vaccination
B. Birth in the United States before 1980.
C. A diagnosis o f varicella by a health-care provider.
D. A self- or parental report o f varicella disease.
E. A verification o f history o f varicella disease by a health-care provider.
4. Which o f the following are characteristics o f breakthrough varicella?
(Indicate all that apply.)
A. Breakthrough varicella cases usually are mild.
B. Breakthrough varicella cases are infectious.
C. In 25% -30%  o f cases, breakthrough varicella has features similar to 
those in unvaccinated persons.
D. A and C  are correct.
E. A, B, and C  are correct.
5. Are breakthrough varicella cases contagious?
A. Yes.
B. No.
C. N o t known.
6. Varicella vaccines....
A. must be refrigerated.
B. are contraindicated in pregnancy.
C. are inactivated vaccines.
D. may be administered starting at age 9 months.
E. contain thimerosal.
In clinical trials, the second dose varicella vaccine...
A. had an estimated 10-year efficacy o f 98%.
B. reduced the risk o f breakthrough varicella by 3.3-fold compared with 
1 dose.
C. induced a titer >5 units gpELISA at 6 weeks postvaccination in 99% of 
vaccine recipients.
D. A and B are correct.
E. A, B, and C  are correct.
8. In the prevaccine era, varicella resulted in how many hospitalizations 
and deaths annually?
A. Very few hospitalizations or deaths.
B. Approximately 5,000 hospitalizations and 50 deaths.
C. Approximately 11,000 hospitalizations and 100—150 deaths.
D. Approximately 20,000 hospitalizations and 200 deaths.
9. Which o f the following statements are characteristics o f the 
epidemiology o f varicella in the United States 10 years after the 
implementation o f the 1-dose vaccination program as documented in 
the active surveillance sites? (Indicate all that apply.)
A. Varicella incidence declined 90% compared with the prevaccine era.
B. Decline in incidence was observed in all age groups, even those not 
targeted for vaccination.
C. Outbreaks continue to occur.
D. More than 50% o f reported cases o f varicella occur among vaccinated 
persons.
E. All o f  the above.
10. Combination measles, mumps, rubella, and varicella (MMRV) 
vaccine is licensed for use among all healthy persons aged >12 months.
A. True.
B. False.
11. Which best describes your professional activities?
A. Physician.
B. Nurse.
C. Health educator.
D. Office staff.
E. Other.
12. I plan to use these recommendations as the basis for . ( Indicate all 
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
13. Overall, the length o f the journal report w a s .
A. much too long.
B. a little too long.
C. just right.
D. a little too short.
E. much too short.
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22. These recommendations will improve the quality o f my practice.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
23. The availability o f continuing education credit influenced my 
decision to read this report.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
24. The M M W R  format was conducive to learning this content.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
25. Do you feel this course was commercially biased? (Indicateyes or no; 
i f  yes, please explain in the space provided.)
A. Yes.
B. No.
26. How did you learn about the continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, M M W R  cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. M M W R  subscription.
F. Other.
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